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Abstract 
The Psychological Symptom Cluster Among Women with Breast Cancer Before and 
During Adjuvant Therapy 
 
Hongjin Li, PhD, MS, BSN  
          University of Pittsburgh, 2019 
 
 
 
Women with breast cancer commonly experience multiple psychological symptoms (i.e., fatigue, 
depressive symptoms, anxiety) that cluster together throughout their cancer diagnosis and 
treatment trajectory. Individuals differ substantially in their experience and trajectory of 
psychological symptoms. A number of factors may contribute to these differences in symptom 
experience, including demographic and clinical characteristics. In addition, given the contribution 
of the hypothalamic-pituitary-adrenal (HPA) axis to these contemporaneous symptoms, individual 
differences in genes that regulate the HPA activity may play a role. This dissertation study aimed 
to (1) characterize the clustering of psychological symptoms over time among postmenopausal 
women with early stage breast cancer during the first 18 months of adjuvant therapy, (2) identify 
distinct subgroups of women with breast cancer based on their experience of a cluster of 
psychological symptoms , and (3) assess whether distinct demographic and clinical characteristics 
and variation in genes regulating the HPA axis predict symptom trajectory subgroup membership. 
This study used symptom and genetic data from postmenopausal women with early stage breast 
cancer followed from baseline (pre-adjuvant therapy) to 18 months post-initiation of adjuvant 
therapy. Results showed that most symptom clusters (i.e., psychological, neurocognitive, weight, 
musculoskeletal, vasomotor, urinary, and sexual) existed before adjuvant therapy and were 
relatively stable through the first 18 months of adjuvant therapy. The gastrointestinal symptom 
cluster only appeared at 6 months. Fatigue and symptoms of depression and anxiety clustered 
 v 
together as a psychological symptom cluster over the 18-month period. Two distinct symptom 
subgroups (“all low” and “all high”) were identified based on the trajectories of fatigue, depressive 
symptom and anxiety. The “all low” subgroup had stable low severity of fatigue and depressive 
symptom and a linear decreasing pattern for anxiety over time. The “all high” subgroup had stable 
high severity of fatigue and depressive symptom and a quadratic pattern for anxiety over time. 
Women who were younger in age, had less education, and who received chemotherapy had greater 
likelihood of being in the “all high” symptom subgroup. Variation in genes regulating the HPA 
axis (i.e., FKBP5 rs9394309, NR3C2 rs5525, CRHR1 rs12944712) were associated with 
membership in the “all high” symptom subgroup. The results of this study may help to identify 
women with breast cancer who are at increased risk for psychological symptoms, facilitating the 
development of individualized and preemptive interventions to better manage their symptoms 
during adjuvant therapy. 
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1.0 PROPOSAL INTRODUCTION AND SPECIFIC AIMS 
Breast cancer is the most common cancer among women in the United States. In 2018, it was 
estimated that 266,120 women in the United States were diagnosed with invasive breast cancer 
(Siegel, Miller, & Jemal, 2018). Approximately 80% of women with breast cancer have hormone 
receptor positive disease (Lumachi, Santeufemia, & Basso, 2015), and a minimum of 5 years of 
aromatase inhibitor (AI) therapy is recommended for postmenopausal women with hormone 
receptor positive, early-stage breast cancer with or without chemotherapy (Rugo et al., 2016).  
Many women with breast cancer experience “psychological” symptoms, such as fatigue, 
depressive symptoms, anxiety and sleep disturbances, which may have a detrimental impact on 
their functional status and quality of life (QOL) (Garreau, DeLaMelena, Walts, Karamlou, & 
Johnson, 2006). These psychological symptoms have been reported before and during cancer 
treatment and can persist years after completion of therapy among women with breast cancer 
(Albusoul, Berger, Gay, Janson, & Lee, 2017a; Denieffe, Cowman, & Gooney, 2014; Roiland & 
Heidrich, 2011). Rather than studying single symptoms, emphasis over the past 15 years has 
focused on symptom clusters. A symptom cluster has been defined as two or more symptoms 
that co-occur together (Kim, McGuire, Tulman, & Barsevick, 2005). Increasing evidence shows 
that fatigue, depressive symptoms, anxiety and sleep disturbances usually clustered together 
among women with breast cancer (Bower et al., 2011; Doong et al., 2015; Ho, Rohan, Parent, 
Tager, & McKinley, 2015). To date, most symptom cluster studies have used cross-sectional 
designs and selected predetermined symptoms by identifying the most common symptoms 
among heterogeneous samples of women with breast cancer receiving differing types of 
treatment, such as chemotherapy and radiation therapy (Xiao, 2010). Furthermore, most 
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symptom cluster studies among women with breast cancer have limited their follow-up 
assessment to one year or less during or after treatment (Albusoul, Berger, Gay, Janson, & Lee, 
2017b; Ho et al., 2015; Langford et al., 2016). Few studies have examined how the psychological 
symptom cluster change over time during long-term endocrine therapy or incorporating a 
comprehensive assessment of symptoms specific to the experience of postmenopausal women 
with breast cancer. The trajectory of the psychological symptom cluster during long-term 
endocrine therapy and factors that may aggravate or alleviate this symptom cluster experience in 
women with breast cancer has not been fully described. It is also not clear whether there are 
subgroups of women who are at higher risk for the psychological symptom cluster and whether 
there are demographic and clinical factors (i.e., age, marital status, income, education level, 
treatment characteristics, stage of disease) or genotypic factors (i.e., variations in 
polymorphisms) that may influence the symptom cluster subgroup membership over time. Thus, 
identifying the psychological symptom cluster associated with adjuvant therapy over time and 
determining the factors that are related to the psychological symptom cluster trajectories are 
critical steps in symptom management and ultimately improving women’s QOL.   
Although the reason for the clustering of the psychological symptoms remains unclear. It 
is widely suggested that cytokines may play a role, acting on the central nervous system to induce 
sickness behaviors (Cleeland et al., 2003). Women with breast cancer experience high levels of 
stress from cancer diagnosis and throughout undergoing cancer treatment (i.e., surgery, 
chemotherapy, radiation therapy) with the activation of inflammatory response and are at high risk 
for developing psychological symptoms (Miller, Ancoli-Israel, Bower, Capuron, & Irwin, 2008). 
Peripheral levels of pro-inflammatory mediators are controlled by a number of physiological 
pathways. Key among them is the hypothalamic-pituitary-adrenal (HPA) axis, which has a 
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complex and bidirectional relationship with the immune system (Chrousos, 1995). Activation of 
this pathway and subsequent modulation of levels of pro-inflammatory mediators may contribute 
to individual differences in vulnerability to clusters of psychological symptoms. In support of this 
possibility, research shows that disrupted HPA axis activity has been linked with psychological 
symptoms among cancer patients. Hoyt and his colleagues found that sleep disruption and 
depressive symptom were related to disrupted cortisol activity (Hoyt, Bower, Irwin, Weierich, & 
Stanton, 2016). Similarly, another study showed that a symptom cluster of pain, depressive 
symptom, and fatigue was associated with cortisol and adrenocorticotropic hormone levels among 
women with breast cancer (Thornton, Andersen, & Blakely, 2010). Prolonged activation of the 
HPA axis may lead to glucocorticoid receptor resistance and influence the down-regulation of 
inflammation (Miller et al., 2008). Based on this evidence, variations in genes regulating the HPA 
axis may influence the heterogeneous experience of symptom clusters among cancer patients. 
Therefore, the purpose of this study was to characterize the psychological symptom 
cluster over time using a comprehensive assessment of symptoms experienced by 
postmenopausal women with early stage breast cancer during the first 18 months of adjuvant 
therapy (AI therapy with or without chemotherapy), identify distinct subgroups of women with 
breast cancer based on their experience of the psychological symptom cluster, and assess 
whether distinct demographic and clinical characteristics and variation in genes regulating the 
HPA axis are associated with subgroup membership. Results of this study may help to identify 
women at higher risk of the psychological symptom cluster during adjuvant therapy. Ultimately, 
these results may guide effective symptom cluster assessment and serve as a foundation for 
development of personalized interventions to manage symptoms effectively among women with 
breast cancer receiving adjuvant therapy. 
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The specific aims of the proposed study were: 
Aim 1: To identify symptom clusters at four time points from baseline (pre-adjuvant 
therapy) to the first 18 months of adjuvant therapy in postmenopausal women with early 
stage breast cancer. Exploratory factor analyses were performed at four time points to identify 
symptom clusters using the data from a study of cognitive function and other symptoms in 
postmenopausal women receiving the AI, anastrozole, for early stage breast cancer (R01-
CA107408). Symptoms were comprehensively evaluated in postmenopausal women with breast 
cancer pre-adjuvant therapy and at 6-month intervals up to 18-months post-initiation of adjuvant 
therapy. We hypothesized that by conducting a comprehensive assessment of symptoms at 
regular intervals, unique symptom clusters and stable symptoms within the psychological 
symptom cluster would be identified among women with breast cancer during adjuvant therapy. 
Symptoms were considered stable if they were identified in the same symptom cluster at least 
three follow-up assessments.  
Aim 2: To identify distinct subgroups of women with breast cancer based on the 
severity of the stable symptoms within the psychological symptom cluster from baseline 
(pre-adjuvant therapy) to the first 18 months of systemic adjuvant therapy. We 
hypothesized that at least two distinct subgroups of women with breast cancer would be 
identified based on temporal pattern of symptom severity trajectories across the set of symptoms 
for the psychological symptom cluster. 
Aim 3: To explore the relationship between the demographic and clinical factors 
(age, marital status, employment status, education level, treatment of chemotherapy, stage 
of disease) and genotypic factors (variations in polymorphisms related to HPA axis 
disturbance) and predicted subgroup membership based on the severity of the 
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psychological symptom cluster among women with breast cancer from baseline (pre-
adjuvant therapy) to the first 18 months of adjuvant therapy.  
1.1 BACKGROUND 
1.1.1  Breast cancer prevalence and treatment options 
Breast cancer is the most common cancer among women in the United States. In 2018, it was 
estimated that 266,120 women in the United States would be diagnosed with invasive breast cancer 
(Siegel et al., 2018). Approximately 80% of women with breast cancer have hormone receptor 
positive disease (Lumachi et al., 2015). Due to clear benefits in disease-free survival and reduced 
recurrence, a minimum of five years of third-generation AIs (anastrozole 1 mg tablet once daily, 
letrozole 2.5 mg tablet once daily or exemestane 25mg tablet once daily) is recommended for 
postmenopausal women with hormone receptor positive, early stage breast cancer (Buzdar, 
Robertson, Eiermann, & Nabholtz, 2002; Rugo et al., 2016). 
1.1.2  Sickness behaviors and inflammation 
Farmers have long recognized that sick animals behave differently from other animals, showing 
increased lethargy, and reduced interaction with other animals. In the 1960s, Miller systematically 
evaluated sickness behaviors in animals and suggested that a “factor X” produced by sick animals 
acted in the brain to cause sickness behavior (Holmes & Miller, 1963). In the 1980s, Hart proposed 
that sickness behavior was an adaptive response to infection and it was important to host defenses 
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(Hart, 1988).  Later, it was shown that infectious pathogens stimulated mononuclear phagocytic 
cells and produced a protein (i.e., pro-inflammatory cytokines) to cause sickness behaviors (Kent, 
Bluthé, Kelley, & Dantzer, 1992). These findings suggested a connection between the immune 
system and brain. In the 1990s, pathways by which peripheral pro-inflammatory cytokines can 
access the brain were identified, including neural and humoral routes (Banks, Kastin, & Gutierrez, 
1994). In the neural pathway, different afferent nerves (vagal nerve and trigeminal nerve) are 
activated by cytokines and project to different regions of the brain. In the humoral pathway, 
circulating cytokines reach the brain through circumventricular organs, leaky regions in the blood–
brain barrier or communicate with the brain directly through brain parenchymal cells (Dantzer, 
O'Connor, Freund, Johnson, & Kelley, 2008). 
 Pro-inflammatory cytokines levels are usually higher among cancer patients as a result of 
disease processes and cancer treatment. Research shows that interleukin-6 (IL-6), IL-8, IL-10, and 
tumor necrosis factor alpha (TNF-α) are involved in breast cancer development and metastasis 
induction (Esquivel-Velázquez et al., 2015). Moreover, it has been reported that breast cancer 
survivors have increased levels of IL-6 and TNF-α after cancer treatment, including surgery, 
chemotherapy and radiation therapy (Alfano et al., 2017). 
In the last 15 years, the cytokine-induced model of sickness behavior has been applied to 
cancer populations as a proposed mechanism of the depressive symptoms, anxiety, fatigue, and 
sleep disturbances that patients often experience (Cleeland et al., 2003). Pain, fatigue, sleep 
disturbances, anxiety and depressive symptoms commonly cluster among women with breast 
cancer (Denieffe, Cowman, & Gooney, 2014; Dodd, Cho, Cooper, & Miaskowski, 2010; Doong 
et al., 2015; Gaston-Johansson, Fall-Dickson, Bakos, & Kennedy, 1999; Gehrman, Garland, 
Matura, & Mao, 2016; Golan-Vered & Pud, 2013; Jaremka et al., 2013; Kim, Barsevick, Beck, 
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& Dudley, 2012; Kim, McDermott, & Barsevick, 2014; Langford et al., 2016; Li, Gao, Yu, Zhu, 
& Cao, 2017; Liu et al., 2009; Liu et al., 2012; Moskowitz, Feuerstein, & Todd, 2013; Payne, 
Piper, Rabinowitz, & Zimmerman, 2006; Sanford et al., 2014; So et al., 2009; Starkweather et 
al., 2013; Thornton et al., 2010). Among these psychological symptoms, fatigue has been well 
studied among women with breast cancer. Higher levels of the pro-inflammatory cytokines of  
IL-6, IL-1ra, and TNF-α were associated with fatigue among breast cancer survivors (Bower, 
Ganz, Aziz, Fahey, & Cole, 2003; Collado-Hidalgo, Bower, Ganz, Cole, & Irwin, 2006). 
Building on evidence that cytokines contribute to the cluster of sickness behaviors that 
accompany infectious disease, it has been proposed that the inflammation that accompanies 
cancer diagnosis and treatment results in similar symptom clusters. Indeed, evidence shows that 
pro-inflammatory cytokines and cytokine gene polymorphisms are associated with the 
“psychological” symptom cluster among cancer patients (Doong et al., 2015; Illi et al., 2012; 
Reyes-Gibby et al., 2013; Starkweather et al., 2013).  
1.1.3  Neuroendocrine pathway and symptoms 
Different pathways are involved in the control of peripheral levels of inflammation and the HPA 
axis is one of the primary pathways. Activation of the HPA axis begins with the secretion of 
corticotropin-releasing factor (CRF) from the hypothalamus CRF binds to the receptors on the 
anterior pituitary gland and stimulates the pituitary gland to release adrenocorticotropic hormone 
(ACTH) into peripheral circulation. Finally, when ACTH binds to the receptors on the adrenal 
cortex, cortisol or glucocorticoid is released. To maintain systemic homeostasis, glucocorticoids 
can regulate their own production through negative feedback on hypothalamus and pituitary gland 
(Bonfiglio et al., 2011). Peripheral levels of cortisol play an important role in the control of innate 
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inflammatory responses by activating glucocorticoid receptors within immune cells. Activation of 
glucocorticoids receptors results in down-regulation of inflammatory gene transcription and the 
decreased production and release of pro-inflammatory cytokines (Xavier, Anunciato, Rosenstock, 
& Glezer, 2016). Under conditions of chronic stress, however, the glucocorticoid receptors become 
less sensitive to the action of cortisol, possible as a result of prolonged exposure to heightened 
levels (Miller, Ancoli-Israel, Bower, Capuron, & Irwin, 2008). In this situation, activation of the 
HPA axis is less effective at down-regulating inflammation, and prolonged elevation of peripheral 
inflammatory mediators is observed. In support of this, consistent data shows and an association 
of distress with elevated levels of pro-inflammatory cytokines, such as IL-6, TNF-α, and C-
reactive protein (CRP) (Doong et al., 2015; Oliveira Miranda et al., 2014; Starkweather, Lyon, & 
Schubert, 2013; Young, Bruno, & Pomara, 2014).  
The disrupted HPA axis has been linked with “psychological” symptoms among cancer 
patients. Hoyt and his colleagues have found that sleep disruption and depressive symptom were 
related to disrupted cortisol activity (Hoyt et al., 2016), which implies that HPA axis is the possible 
underlying mechanism of these symptoms. Another study also found that a symptom cluster of 
pain, depressive symptom, and fatigue is associated with increased levels of cortisol and 
adrenocorticotropic hormone among women with breast cancer (Thornton, Andersen, & Blakely, 
2010). 
1.1.4  Cancer treatment, inflammation and the HPA axis 
Research shows that chemotherapy and radiation therapy can increase inflammation in patients 
with breast cancer because of treatment-related damage to tissue (Grivennikov, Greten, & Karin, 
2010). Moreover, the HPA axis can be suppressed by chemotherapy and radiation therapy among 
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cancer patients (Schmiegelow et al., 2003), which may contribute to increased inflammation. Other 
factors, such as psychological stress related to cancer diagnosis and cancer treatment, can induce 
inflammation and disrupt the HPA axis as well (Powell, Tarr, & Sheridan, 2013; Spiegel, Giese-
Davis, Taylor, & Kraemer, 2006). Although no study has evaluated the influence of endocrine 
therapy on inflammation and the HPA axis among women with breast cancer, a significant body 
of work suggests that higher levels of estrogen have anti-inflammatory effects (Kovats, 2015) and 
can stabilize the function of the HPA axis (De Nicola, Saravia, Beauquis, Pietranera, & Ferrini, 
2006). It is still controversial whether estrogen directly regulates the HPA axis or indirectly 
regulates the HPA axis through the immune system.  
Thus, we propose that as a result of cancer treatments and chronic psychological stress, 
the HPA axis and innate immune inflammatory response are activated, which have complex and 
bi-directional communications. Prolonged activation of the HPA axis may lead to decreased 
glucocorticoid receptor sensitivity and thus increased levels of inflammatory mediators. 
Therefore, the innate immune system and neuroendocrine system interact together to influence 
CNS function, and ultimately may contribute to the onset of psychological symptoms (see Figure 
1).  
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Figure 1 Relationship Among Breast Cancer  and Cancer Treatment, Stress, Inflammation, HPA Axis, and 
Psychological Symptoms 
1.2 LITERATURE REVIEW 
Two literature reviews were conducted related to 1) the phenotype of the psychological symptom 
cluster and 2) the biology and impact of genetics related to the HPA axis on the psychological 
symptom cluster. Three literature databases, PubMed, PsycINFO, and CINAHL, were searched 
for each review. The terms “breast cancer” and “symptom clusters” or “concurrent symptoms” or 
“coexisting symptoms” or “multiple symptoms” or “co-occurring symptoms” were used for the 
review of phenotype of the psychological symptom cluster.  A review of functional SNPs of 
genes associated with the HPA axis in the general population was conducted. Search terms 
“single nucleotide polymorphism”, “gene” and “HPA axis” were used for the review of 
functional SNPs of genes associated with the HPA axis in the general population. 
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1.2.1  Review of phenotype of the psychological symptom cluster 
1.2.1.1 Identification of symptom clusters and methodological issues 
One of the most common identified symptom clusters among women with breast cancer has been 
a psychological symptom cluster (Denieffe, Cowman, & Gooney, 2014; Dodd, Cho, Cooper, & 
Miaskowski, 2010; Doong et al., 2015; Gaston-Jahansson, Fall-Dickson, Bakos, & Kennedy, 
1999; Gehrman, Garland, Matura, & Mao, 2016; Golan-Vered & Pud, 2013; Jaremka et al., 2013; 
Kim, Barsevick, Beck, & Dudley, 2012; Kim, McDermott, & Barsevick, 2014; Langford et al., 
2016; Li, Gao, Yu, Zhu, & Cao, 2017; L. Liu et al., 2009; Liu et al., 2012; Moskowitz et al., 2013; 
Payne, Piper, Rabinowitz, & Zimmerman, 2006; Sanford et al., 2014; So et al., 2009; Starkweather 
et al., 2013; Thornton, Anderson, & Blakely, 2010). This symptom cluster has been named 
differently across studies, such as “psychoneurological symptoms” (Kim, McDermott, & 
Barsevick, 2014; Starkweather et al., 2017), “psychological symptoms” (Langford et al., 2016; 
Carmen W Sullivan et al., 2018), “emotional symptoms” (Sarenmalm, Browall, & Gaston-
Johansson, 2014), “behavioral symptoms” (Bower, 2008; Fagundes, LeRoy, & Karuga, 2015) and 
“treatment-related symptoms” (Albusoul, Berger, Gay, Janson, & Lee, 2017; Kim, Barsevick, 
Tulman, & McDermott, 2008). There has been a great deal of variability in the symptoms which 
constitute the psychological symptom cluster among women with breast cancer. These variations 
can be attributed to heterogeneous samples across studies and differences in study designs, 
measurement and analytic approaches.  
1.2.1.2 Samples of previous studies 
Most previous symptom cluster studies have used a heterogeneous sample combining 
premenopausal and postmenopausal women with early stage of breast cancer. Only four studies 
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evaluated symptom clusters exclusively in postmenopausal women (Ho et al., 2015; Sarenmalm, 
Browall, & Gaston-Jahansson, 2014; Sarenmalm, Ohlen, Jonsson, & Gaston-Johansson, 2007; 
Roiland & Heidrich, 2011). Sixteen studies evaluated symptom clusters among women receiving 
adjuvant treatment (chemotherapy, radiation therapy and/or endocrine therapy) (Dodd, Chi, 
Cooper, & Miaskowski, 2010; Gaston-Jahansson, Fall-Dickson, Bakos, & Kennedy, 1999; Ho et 
al., 2015; Jaremka et al., 2013; Sarenmalm, Browall, & Gaston-Johansson, 2014; Sarenmalm, 
Ohlen, Jonsson, & Gaston-Johansson, 2007; Kim, Barsevick, Tulman, & McDermott, 2008; Kim, 
Barsevick, Beck, & Dudley, 2012; Kim et al., 2009; Kim, McDermott, & Barsevick, 2014; 
Marshall et al., 2016; Moskowitz, Feuerstein, & Todd, 2013; Roiland & Heidrich, 2011; So et al., 
2009; Thornton et al., 2010; Wilmoth, Coleman, & Wahab, 2009), six studies evaluated women 
before or after surgery (Bender, Ergÿn, Rosenzweig, Cohen, & Sereika, 2005; Denieffe, Cowman, 
& Gooney, 2014; Doong et al., 2015; Kenefick, 2006; Li, Gao, Yu, Zhu, & Cao, 2017; 
Starkweather et al., 2013), 14 studies evaluated women receiving chemotherapy (Albusoul, 
Berger, Gay, Janson, & Lee, 2017; Browall, Brandberg, Nasic, Rydberg, Bergh, Rydén, Xie, 
Eriksson, & Wengström, 2017; Byar, Berger, Bakken, & Cetak, 2006; Golan-Vered & Pud, 2013; 
Gwede, Small, Munster, Andrykowski, & Jacobsen, 2008; Hsu et al., 2017; Langford et al., 2016; 
Liu et al., 2009; Liu et al., 2012; Payne et al., 2006; Phligbua et al., 2013; Sanford et al., 2014; 
Starkweather et al., 2017; Sullivan et al., 2018), and one study examined women undergoing 
radiation therapy (Matthews, Schmiege, Cook, & Sousa, 2012). While there are reports of studies 
examining different symptoms among women with breast cancer during endocrine therapy (Ganz, 
Petersen, Bower, & Crespi, 2016; Rosenberg, Stanton, Petrie, & Partridge, 2015), only two studies 
have evaluated symptom clusters among women with breast cancer before or during endocrine 
therapy (Glaus et al., 2006; Kidwell et al., 2014). Kidwell et al. (2014) indicated that a cluster of 
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sleep quality, concentration, fatigue, anxiety and depressive symptom was present before AI 
therapy and these pre-treatment symptoms may negatively influence adherence to AI therapy. 
Glaus et al. (2006) found that menopausal symptoms (i.e., hot flashes/sweats, tiredness, weight 
gain, vaginal dryness, decreased sexual interest) and fatigue clustered together among women with 
breast cancer during endocrine therapy. Since AI therapy is the mainstay of endocrine therapy for 
postmenopausal women with hormone receptor positive disease, and experts emphasize the 
importance of homogenous samples in terms of cancer treatment in symptom clusters research as 
a research priority (Barsevick, 2016; Miaskowski, 2016), more studies are needed to identify the 
unique symptom clusters experienced by postmenopausal women during AI therapy.  
1.2.1.3 Methodologies in previous studies 
To date, there have been two main approaches to examine symptom clusters (Miaskowski, 
2016). One approach is to select predetermined symptoms by identifying the most common 
symptoms experienced from previous studies. Correlations among symptoms, using concurrent 
symptoms and identification of subgroups of patients with similar symptom experiences were 
commonly used to identify “clusters of symptoms” or “clusters of patients” in this approach. Dodd 
et al. (2010) used cluster analysis and identified four subgroups based on a pre-determined 
symptom cluster of pain, fatigue, sleep disturbances, and depressive symptom. The other approach 
is to examine a comprehensive list of symptoms which may be experienced and identify clusters 
through analytic techniques such as exploratory factor analysis (EFA), or identification of 
subgroups of patients with similar symptom experiences. Using this analytic strategy, Kim et al. 
(2008) identified psychoneurological and upper gastrointestinal (GI) symptom clusters from 20 
symptoms commonly experienced by women with breast cancer. Subsequently, Kim et al. (2014) 
identified three subgroups of women based on their experience of the psychoneurological cluster 
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using the same sample from previous study. Browall et. al (2017) identified physical, GI and 
emotional symptom clusters among women with breast cancer during chemotherapy. Subgroups 
of patients with similar symptom experiences can be identified from a comprehensive list of 
symptoms with this second approach by using group-based trajectory modeling or latent class 
growth analysis. Gwede et. al (2008) identified “high-symptom burden” and “low symptom 
burden” subgroups using 23 symptoms experienced by women with breast cancer. 
For the “predetermined symptoms” approach, although there is evidence and background 
to support the appearance of a predetermined set of symptoms and their shared biological 
mechanisms, given the fact that symptoms may change over time and different symptoms can be 
associated with different treatments, some important symptoms may be overlooked. The second 
approach is more empirically-based and reliable because it takes into consideration a 
comprehensive list of symptoms that may be experienced. More symptom clusters may be found 
compared to the approach using a predetermined set of symptoms. Therefore, more studies with 
larger sample sizes are needed to identify symptom clusters using a comprehensive list of 
symptoms. 
1.2.1.4 Changes in symptom cluster over time 
Evidence documenting how symptom clusters change over time is inconsistent across studies. An 
increasing number of studies have found that symptom clusters are dynamic over time during and 
after the conclusion? of treatment (Albusoul, Berger, Gay, Janson, & Lee, 2017; Hsu et al., 2017; 
Kenefick, 2006; Sanford et al., 2014; Starkweather et al., 2017). For example, symptoms clusters 
were more changeable over the first six months after initiating chemotherapy in women with breast 
cancer (Starkweather et al., 2017). Symptom distress declined slowly from discharge to six months 
post-discharge, after surgery (Kenefick, 2006). Other studies have found that the psychological 
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symptom cluster is relatively stable over time with minor changes in the number of symptoms and 
the specific symptoms within each symptom cluster (Kim et al., 2009; Sullivan et al., 2018). Most 
longitudinal studies of symptom clusters are among women with breast cancer during 
chemotherapy. The literature has not featured any studies that examined changes in the 
psychological symptom cluster over time during long-term AI therapy.  
1.2.1.5 Identification of subgroup membership and their correlates 
It is not clear whether subgroups of women with breast cancer exist based on their experience of 
the psychological symptom cluster during long-term AI therapy (with or without chemotherapy). 
Among women with breast cancer, the variability of the experience of psychological symptom 
cluster has been reported between individuals during other treatments. For example, different 
patient subgroups (all low, mild, moderate, all high) were found based on the experience of pain, 
fatigue, sleep disturbances, depressive symptom among women with breast cancer during 
receiving chemotherapy (Kim, McDermott, & Barsevick, 2014). However, no studies to date 
have examined subgroups of women who are at risk for higher severity of psychological 
symptom cluster during AI therapy.  
Once subgroups are identified, it is important to understand individual susceptibility to 
symptoms by identifying the demographic, clinical and genotypic factors related to membership 
in those symptom cluster subgroups. This critical information may be used to identify women 
who are at high risk for greater symptom severity and help nurses to provide personalized 
symptom management care. Research suggests that previous cancer treatment, pre-treatment 
symptom severity, chemotherapy use, advanced disease stage, younger age, higher education 
level, lower income, less likely to be employed and less likely to be married are associated with 
higher severity of symptom clusters (Dodd, Cho, Cooper, & Miaskowski, 2010; Gehrman, 
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Garland, Matura, & Mao, 2016; Kim, Barsevick, Tulman, & McDermott, 2008; Kim, Barsevick, 
Beck, & Dudley, 2012; Kim et al., 2009; Langford et al., 2016; Liu et al., 2009). All the above 
studies examining the demographic and clinical factors associated with the psychological 
symptom cluster were among women with breast cancer receiving chemotherapy, radiation 
therapy or after surgery. To date, no studies have examined the demographic, clinical and 
genotypic factors associated with the psychological symptom cluster among women with breast 
cancer receiving endocrine therapy. 
1.2.2  Review on biology and impact on genetics on the psychological symptom cluster 
The mechanisms underlying the psychological symptom cluster among women with breast 
cancer are not entirely clear. For the past 15 years, researchers have explored the mechanism of 
cancer symptoms using the cytokine-induced sickness behavior model (Cleeland et al., 2003). It 
is widely proposed that inflammation plays a role in the induction of sickness symptoms. Given 
the role of the HPA axis in the modulation of inflammatory processes, we propose that the 
disruption of HPA axis may also contribute to the experience of symptoms. Only two studies 
have evaluated the relationship between hormones related to the HPA axis and symptom clusters 
among breast cancer patients. The psychological symptom cluster has been shown to be 
positively associated with HPA biomarkers and neuroendocrine hormones (Payne et al., 2006; 
Thornton et al., 2010). Payne et al. (2006) conducted a pilot study among 22 women with breast 
cancer receiving chemotherapy and found a positive association between HPA biomarkers 
(melatonin, bilirubin, cortisol, serotonin) and fatigue, sleep disturbances, and depressive 
symptoms. Later, Thoronto et al. (2010) evaluated the sympathetic nervous system and HPA 
axis, and found that four neuroendocrine hormones (cortisol, adrenocorticotropic hormone, 
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epinephrine, norepinephrine) were positively related to a symptom cluster of pain, fatigue and 
depressive symptom.  Additional research is warranted to confirm this mechanism. Thus, it is 
important to explore the biological mechanism related to the disrupted HPA axis underlying the 
psychological symptom cluster among women with breast cancer receiving adjuvant therapy.  
In 2016, NINR established a National Institutes of Health Symptom Science Model 
(Cashion & Grady, 2015) to lead symptom science and emphasize the importance of 
implementation of genomics and “omics science” in developing strategies for personalized 
symptom prediction and management. Based on the evidence that genetic variability in cytokine 
genes may influence the experience of psychological symptoms among cancer patients (Doong et 
al., 2015;Illi et al., 2012), and genetic variability related to the HPA axis may influence the 
experience of depressive symptoms, anxiety and sleep disturbance in other populations 
(Buttenschøn et al., 2017; Jiang et al., 2016; Suzuki et al., 2014), more studies are needed to 
clarify additional biological mechanisms and explore the impact of genetic variability related to 
the HPA axis on the psychological symptom cluster in women with breast cancer. 
Based on knowledge that the HPA axis plays a key role in the control of peripheral levels 
of proinflammatory mediators that communicate with the central nervous system to coordinate 
comorbid psychological symptoms, we focused only on genes and SNPs that directly relate to 
the HPA axis. A review of functional SNPs of genes associated with the HPA axis in the general 
population was conducted. Search terms “single nucleotide polymorphism”, “gene” and “HPA 
axis” were used in the initial search, which identified 33 genes and 118 SNPs. We then employed 
a review of the literature to arrow our examination of genes to those that play a role in HPA 
regulation (Arnett, Muglia, Laryea, & Muglia, 2016). Genes related to glucocorticoid receptors 
(NR3C1, FKBP5), mineralocorticoid receptor (NR3C2), and corticotropin-releasing hormone 
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(CRHR1, CRHR2, CRHBP) were identified. Finally, a list of 51 functional SNPs in these 6 
genes were selected (See Table 1).   
Table 1 Proposed Single Nucleotide Polymorphisms Associated with the Hypothalamic Pituitary Adrenal 
Axis 
Gene Name Function SNP 
NR3C1 Glucocorticoid 
receptor, GR 
Receptor for glucocorticoids, function as 
a transcription factor that binds to 
glucocorticoid response elements, and as 
a regulator of other transcription factors; 
affects immune and inflammatory 
responses, reproduction, central nervous 
system, cardiovascular function, cellular 
proliferation and differentiation in target 
tissues (Siamatras & Stratakis, 2016); 
regulates negative feedback of the HPA 
axis (Laryea, Muglia, Arnett, & Muglia, 
2015); NR3C1 mutation can cause 
glucocorticoid resistance (Vitellius et al., 
2016). Polymorphisms in NR3C1 are 
associated with depression (Schatzberg 
et al., 2014). 
rs41423247 
rs258747 
rs10482605 
rs1800445 
rs6191 
rs258813 
rs33388 
rs10052957 
rs6198 
rs6195 
rs6189 
rs6190 
rs1866388 
rs8192496 
rs2267715 
CRHR2 Corticotropin 
Releasing Hormone 
Receptor 2 
High affinity for CRH, binds to both 
CRH and urocortin. CRH involved in 
coordinating the endocrine, autonomic, 
and behavioral responses to stress and 
appetitive behaviors (RefSeq, 2011). 
Activation of CRHR2 is related to 
anxiety, and memory deficit under stress 
(Todorovic et al., 2007). 
rs2284218 
rs255098 
rs3779250 
FKBP5 FK506 Binding 
Protein 5 
Co-chaperone of hsp90 and modulates 
GR sensitivity. Polymorphisms in 
FKBP5 are associated with differences 
in GR sensitivity, stress hormone system 
regulation (Binder, 2009), and mood 
disorders (O’Leary et al., 2013). 
rs1360780 
rs3800373 
rs9470080 
rs4713916 
rs9296158 
rs9394309 
rs3777747 
rs17542466 
rs2766533 
rs9380526 
rs9394314 
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rs2817032 
rs2817040 
rs7753746 
rs4713902 
rs7748266 
rs7757037 
CRHR1 Corticotropin 
Releasing Hormone 
Receptor 1 
Binds CRH, major regulators of HPA 
axis following chronic stress (Ramot et 
al., 2017). The encoded protein is 
essential for the activation of signal 
transduction pathways that regulate 
diverse physiological processes 
including stress, reproduction, immune 
response and obesity (RefSeq, 2016). 
rs17689918 
rs28364032 
rs4458044 
rs242924 
rs1768996 
rs12944712 
rs12938031 
rs4792887 
rs1396862 
rs878886 
rs17763104 
rs110402 
rs242948 
rs1876828 
rs17689882 
rs12936511 
rs242939 
rs1876831 
NR3C2 Mineralocorticoid 
receptor, MR 
Receptor for both mineralocorticoids 
(MC) and glucocorticoids (GC).
Binds to mineralocorticoid response
elements (MRE) and transactivates target
genes. Variation in NR3C2 and
polymorphisms are associated with
depression (Vinkers et al., 2015),
cognitive abilities (Keller et al., 2017),
blood pressure and hypertension (van
Leeuwen et al., 2010).
rs5525 
rs4835488 
rs10213471 
rs17484245 
rs7694064 
rs2070951 
rs10473984 
CRHBP Corticotropin 
Releasing Hormone 
Binding Protein 
Regulating glucocorticoid reactivity in 
response to stress; prevents inappropriate 
activation of CRH by binding the CRH 
complex; regulates physiological 
reactions, metabolic function and 
oncogenesis (Borowski et al., 2015; Nan, 
Dorgan, & Rebbeck, 2015)  
rs7718461 
rs1875999 
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1.3 PRELIMINARY STUDY 
Symptom Clusters in Women with Breast Cancer Before Adjuvant Therapy (Li, Sereika, & 
Bender, 2018) 
This was a secondary analysis of symptom data collected at baseline (before adjuvant therapy) 
from an IRB approved prospective repeated measures study of cognitive function in 
postmenopausal women receiving the AI, anastrozole, for early stage breast cancer (R01-
CA107408) (Bender et al., 2015). To identify the symptom clusters prior to initiation of adjuvant 
therapy (baseline), the secondary analysis included 334 postmenopausal women with breast cancer 
who would receive AI therapy only (n=212) and who would receive chemotherapy followed by 
AI therapy (n=122). We used information on 47 symptoms collected prior to adjuvant therapy, 
obtained from a comprehensive battery of symptom assessment tools. Following identification of 
the prevalence of individual symptoms, distinct symptom clusters were determined by conducting 
exploratory factor analysis using principal axis factoring as the extraction method with the promax 
rotation method. The most prevalent individual symptoms were perceived cognitive impairment 
(98.8%), followed by anxiety symptoms (97.6%), depressive symptoms (83.9%), fatigue (81.5%), 
general aches and pains (73.7%), and breast sensitivity (72.2%). Five distinct symptom clusters 
were identified: neurocognitive, musculoskeletal, psychological, hormonal, and urinary (see Table 
2).  
Table 2 Symptoms within each symptom cluster before adjuvant therapy 
Symptom Cluster Symptoms in the Cluster Symptom Cluster Symptoms in the Cluster 
Neurocognitive Difficulty concentrating Psychological Fatigue 
Easily distracted Tendency to take naps 
Forgetfulness Avoidance of social affairs 
Perceived cognitive function Depressive symptoms 
Excitability Tension-anxiety 
Musculoskeletal General aches and pains 
Joint Pain 
Urinary Difficulty with bladder control at 
other times 
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Distinct symptom clusters were present among women with breast cancer before adjuvant 
therapy. Results of this study suggests that the psychological symptom cluster, which consists of 
fatigue, depressive symptoms, tension-anxiety, tendency to take naps, and avoidance of social 
affairs, was highly prevalent and existed among women with breast cancer before they began 
adjuvant therapy. This preliminary study provided the foundation for our investigation of the 
psychological symptom cluster and change in this symptom cluster over the first 18 months of 
adjuvant therapy. Furthermore, it is critical to examine whether baseline symptom severity is 
associated with the severity of symptom clusters or AI discontinuation at after 12 months and 18 
months of AI therapy for future studies.  
1.4 THEORETICAL FRAMEWORK 
The Symptoms Experience Model (SEM) proposed by Armstrong (2003) is a comprehensive 
theory that is useful in guiding research about symptom clusters and it will be used to guide this 
study focusing on the identification of symptom clusters, and the predictors and subgroup 
membership of the predicted psychological symptom cluster trajectories (see Figure 2). In this 
model, symptom is conceptualized as the “perception of the frequency, intensity, distress, and 
meaning occurring as symptoms are produced and expressed” (Armstrong, 2003, p602).  
According to Armstrong (2003), symptoms are usually “being influenced by the occurrence 
attributes of other symptoms” and seldom occur alone. Women with breast cancer may 
experience multiple symptom clusters with disease or treatment. Consistent with this model, we 
Muscle stiffness 
Pain  
Difficulty with bladder control 
when laughing or crying 
Hormonal Hot flashes 
Night sweats 
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measured symptom frequency/prevalence and symptom severity experienced by women with 
breast cancer during AI therapy. 
The SEM has three components, antecedents, symptoms/symptom clusters, and 
consequences. Antecedents can be categorized into demographic (i.e., age, marital status, race and 
education), clinical (i.e., stage of disease, pre-treatment symptom severity, whether received 
chemotherapy) and genotypic (i.e., polymorphisms of genes related to HPA axis disturbance) 
factors. Consequences include adjustment to illness, quality of life, mood, functional status, 
disease progression and survival. From the SEM’s perspective, symptoms are multidimensional 
with different frequencies, intensities and distress levels. Multiple symptoms may occur together, 
and antecedents, symptoms and consequences can influence and interact with each other.  
Figure 2 Conceptual Framework of the Proposed Dissertation Study 
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1.5 SIGNIFICANCE AND INNOVATION 
1.5.1  Significance 
In the United States, the median age at diagnosis among women with breast cancer is 62 years 
(American Cancer Society, 2015), which means that most women with  breast cancer are 
postmenopausal at diagnosis. AI therapy is the mainstay of endocrine therapy for 
postmenopausal women with hormone receptor positive disease (Rugo et al., 2016).  
 Great emphasis has been placed on symptom cluster research within last 15 years. Women with 
breast cancer usually experience multiple co-occurring symptoms or symptom clusters with 
treatment (Nguyen et al., 2011). The psychological symptom cluster, which usually comprises 
fatigue, depressive symptoms, anxiety and sleep disturbances, has been reported before and 
during cancer treatment among women with breast cancer (Ho et al., 2015; Kim, Barsevick, 
Tulman, & McDermott, 2008).  This symptom cluster has a negative impact on women’s 
functional status and can compromise their QOL (Dodd, Miaskowski, & Paul, 2001). However, 
most symptom cluster studies have evaluated this cluster during chemotherapy and radiation 
therapy among women with breast cancer. Few studies have conducted a comprehensive 
assessment of co-occurring symptom clusters during adjuvant endocrine therapy, especially AI 
therapy. Little evidence exists regarding subgroups of women who may be at greater risk for 
higher severity of the psychological symptom cluster during AI therapy and the demographic, 
clinical, and genotypic factors that characterize them. Identifying patterns of symptom 
presentation during AI therapy and individuals who are most vulnerable to severe symptom 
clusters can facilitate preemptive interventions to manage symptoms together and ultimately 
improve adherence to AI therapy and QOL for patients.  
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This proposed study will also help us determine the demographic, clinical and genotypic risk 
factors associated with the psychological symptom cluster. The results of this work will (1) help 
nurses and healthcare providers to identify and screen women with breast cancer who are at 
higher risk of greater severity of psychological symptom cluster and (2) serve as a foundation for 
the development of individualized interventions to better manage those symptoms effectively 
among women with breast cancer receiving adjuvant therapy. The association between genes, 
polymorphisms and symptoms will provide further support for the role of HPA axis mechanism 
in the clustering of psychological symptoms. 
This study fits well with the mission of National Institute of Nursing Research (NINR) in 
2016—promoting personalized health strategies and examination of the underlying mechanisms 
of symptoms experienced by individuals with cancer (Grady, 2017) and the call from NINR for 
Symptom Cluster Characterization in Chronic Conditions (PA-17-462). Moreover, symptoms in 
the psychological symptom cluster are aligned with the top priority symptoms (i.e., fatigue, pain, 
sleep disturbance, cognitive impairment, chemotherapy-induced peripheral neuropathy and 
psychological distress) identified by the Oncology Nursing Society (Knobf et al., 2015). 
1.5.2  Innovation 
The proposed study is innovative because it will be the first study to extend the description of 
symptom clusters over time, identify subgroups of women based on their experience of the 
psychological symptom cluster and explore its demographic, clinical factors and genotypic 
predictors among women with breast cancer from pre-adjuvant therapy through the first 18 
months of adjuvant therapy (AI therapy with or without chemotherapy). It uses a more reliable 
and empirically sound approach to identify symptom clusters by evaluating 48 symptoms that 
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may be experienced by women receiving adjuvant therapy with a broad symptom assessment. 
Most previous studies have used selected predetermined symptoms based on the most common 
symptoms reported in the literature; therefore, some important symptoms may be overlooked. 
Lastly, it will be the first study to explore the association between variations in gene 
polymorphisms related to the HPA axis disturbance and trajectory subgroup membership based 
on the intensity of the psychological symptom cluster among women with breast cancer. 
1.6 RESEARCH METHODS 
1.6.1  Study design 
This is an analysis of existing symptom data and newly generated genomic data from a 
prospective cohort repeated measures study of cognitive function in postmenopausal women 
receiving the AI, anastrozole, for early stage breast cancer (R01-CA107408) (Bender et al., 
2015). The current study will include two groups of postmenopausal women with early stage 
breast cancer who have completed surgery: women who were prescribed either anastrozole 
therapy only (AnastOnly) and women prescribed chemotherapy followed by anastrozole therapy 
(ChemoAnast). Symptom data were collected every 6 months from baseline (pre-adjuvant 
therapy) to 18-months post initiation of adjuvant therapy (see Table 3). Genetic data were 
collected via blood or saliva samples. 
Table 3 Symptom Assessments by Time Point 
Group Pre-chemo Chemotherapy Pre-AI 6 Months AI 12 Months AI 18 Months AI 
ChemoAnast X (baseline) Yes X X X N/A 
AnastOnly N/A No X (baseline) X X X 
Note: All women with breast cancer completed the baseline assessment after primary surgery but prior to any 
adjuvant therapy. For women in the ChemoAnast group, baseline is before chemotherapy. For women in the 
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AnastOnly group, baseline is before anastrozole therapy. Women in the ChemoAnast group completed follow-up 
symptom assessments after chemotherapy but prior to anastrozole therapy, 6, and 12 months after the initiation of 
anastrozole. Women in the AnastOnly group completed follow-up symptom assessments at 6, 12, and 18 months 
after the initiation of anastrozole therapy.  
Note: AI: aromatase inhibitor; AnastOnly: women prescribed anastrozole therapy only; ChemoAnast: women 
prescribed chemotherapy followed by anastrozole therapy. 
1.6.2  Setting and recruitment 
Women with breast cancer were recruited from the Breast Cancer Program of the Hillman Cancer 
Institute, consisting of Magee-Women's Hospital, Hillman Cancer Center, and Shadyside Hospital 
from 2005 to 2015. The original study was approved by the University of Pittsburgh Institutional 
Review Board, all participants provided written informed consent. This study will be sent to the 
University of Pittsburgh Institutional Review Board to obtain approval. 
 A total of 354 women with breast cancer (127 ChemoAnast and 227 AnastOnly) were 
enrolled in the study. Inclusion criteria included: (1) women newly diagnosed with stage I, II or 
IIIA breast cancer; (2) ≤75 years of age; (3) postmenopausal; (4) scheduled to receive 
chemotherapy plus anastrozole or anastrozole alone; (5) able to speak and read English; and (6) 
completed a minimum of 8 years of education. Exclusion criteria included: (1) self-report of 
hospitalization for psychiatric illness within the last 2 years; (2) prior diagnosis of neurologic 
illness, such as stroke, multiple sclerosis, dementia syndrome, or Parkinson’s disease, or of HIV-
related dementia, or chronic fatigue syndrome; 3) prior diagnosis of cancer; or 4) clinical evidence 
of distant metastases.  
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1.6.3  Sample size justification 
This study was a secondary analysis of data and blood/saliva samples collected from women with 
breast cancer receiving AI therapy who participated in the AIM study and hence the sample size 
for this study is fixed. For Specific Aim 1 to identify symptom clusters for women with breast 
cancer receiving AI therapy, the recommendation of minimum sample size in exploratory factor 
analysis is 100 (MacCallum, Widaman, Zhang, & Hong, 1999), with the criteria “100 = poor, 
200 = fair, 300 = good, 500 = very good, ≥1000 = excellent” (Comrey & Lee, 2013) and the 
participant-to-variable ratio being at least 5 (MacCallum et al., 1999). The sample size was 
sufficient to conduct the EFA at baseline (N=354, 354/48=7.4) and 6 months (N=288, 288/48=6). 
Even though based on the rule of thumb, we lost some precision to conduct the EFA at 12 (N=205, 
205/48=4.2) months and 18 (N=162, 162÷48=3.4) months, the minimum sample size for 
exploratory factor analysis is also dependent on other factors, such as the communality of the 
variables, size of factor loadings, and degree of over determination of the factor (MacCallum et 
al., 1999; Preacher & MacCallum, 2002). To increase the precision to conduct the EFA, we made 
sure the communality of the variables should be greater than 0.60, symptom-total correlations must 
be greater than 0.25 (Ferketich, 1991), a minimum of two variables per factor and each factor 
should have loadings higher than 0.40 (Browne, 2001). Participants who have symptom data for 
at least two time points from baseline (T0) to 18 months (T3) after adjuvant therapy (N=292) were 
included to measure within-person symptom trajectories for Specific Aim 2. Literature on 
trajectories of psychological symptoms or symptom clusters among women with breast cancer 
suggest that the number of subgroups based on similarities in their experience of symptom clusters 
may range from two to five (Avis, Levine, Case, Naftalis, & Zee, 2015; Bidstrup et al., 2015; 
Comrey & Lee, 2013; Donovan, Gonzalez, Small, Andrykowski, & Jacobsen, 2013; Park, Chun, 
28 
Jung, & Bae, 2017; Sanford et al., 2014). Among different depressive or anxiety symptom 
trajectory studies, linear or quadratic polynomial trajectories are the most common trajectories 
identified. A minimum trajectory group size of 47 is required to estimate a reliable quadratic 
trajectory (Avis, Levine, Case, Naftalis, & Zee, 2015; Murphy et al., 2015; Rottmann et al., 2016), 
which is 16% (47/292=16%) of the sample size available for this proposed study. Thus the sample 
size is much higher than the recommended group membership probability of 5% based on the 
group size of 292 (Andruff, Carraro, Thompson, Gaudreau, & Louvet, 2009). Since the suggested 
number of subgroups ranged from two to five, we had sufficient sample size to estimate maximum 
of five quadratic trajectories. 
For Specific aim 3, data was analyzed in an exploratory manner using logistic regression 
among women with breast cancer who also have a genetic sample and symptom data (n=167).  
1.6.4  Measures 
1.6.4.1 Demographic and clinical characteristics 
Self-reported demographic (e.g., age, race, education level, occupation type, marital status) and 
clinical (disease stage, and types of treatments) characteristics of participants were collected at 
baseline.  
1.6.4.2 Symptoms 
A comprehensive battery of measures was used to assess the symptoms that participants 
experienced before and every 6 months through the first 18 months of adjuvant therapy. To 
standardize the scaling of symptom scores among the instruments used, the symptom scores will 
be transformed to a 0-100 scale. Of the 47 symptoms evaluated, 42 symptoms were assessed 
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with the Breast Cancer Prevention Trial (BCPT) Symptom Checklist (Stanton, Bernaards, & 
Ganz, 2005), while the remaining 6 symptoms (fatigue, changes in sleep pattern, anxiety 
symptoms, general pain, depressive symptoms, and perceived cognitive impairment) were 
assessed using the Profile of Mood States (McNair, Lorr, & Droppleman, 1992) (POMS; fatigue, 
anxiety), Brief Pain Inventory-Short Form (Cleeland & Ryan, 1994) (BPI; pain), Beck 
Depression Inventory-II (Beck, Steer, & Brown, 1996) (BDI-II; depressive symptoms), and 
Patient’s Assessment of Own Functioning (Chelune, Heaton, & Lehman, 1986) (PAOFI; 
perceived cognitive ability).  
Two subscales of the POMS (Fatigue/Inertia subscale and Tension/Anxiety subscale) 
were used to measure fatigue and anxiety. The POMS is a self-report measure of mood states, 
with 65 items rated on a 5-point Likert scale format from 0 (not at all) to 4 (extremely) (McNair 
et al., 1992). The POMS-Fatigue/Inertia subscale has 7 items, with a test-retest reliability of .66 
and internal consistency of .94 (McNair et al., 1992). The POMS-Tension/Anxiety subscale has 
9 items, with an internal consistency of .92 and test-retest reliability of .70 (McNair et al., 1992). 
Higher average fatigue and anxiety subscale scores (range 0-4) indicate greater severity of 
fatigue and anxiety.  
The BPI-short form was used to measure pain.  The BPI consists of 9 items assessing 
pain intensity, pain relief treatment or medication and pain interference (Cleeland & Ryan, 
1994). It has well-established reliability and validity to assess pain among patients with cancer 
(Caraceni, 2001; Tittle, McMillan, & Hagan, 2003). For this study, 4 items related to pain 
intensity ranging from 0 (no pain) to 10 (pain as bad as you can imagine) were used. Higher 
average pain intensity scores indicate severe pain.  
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The BDI-II, is a 21-item, self-report measure of depressive symptom severity and items 
are rated on a 4-point Likert scale from 0 (no symptom) to 3 (severe symptom) (Beck et al., 
1996). High reliability and validity have been demonstrated for the BDI (Wang & Gorenstein, 
2013). The BDI-II measures somatic symptoms (items 15-21) and mood/cognitive symptoms 
(items 1-14) (Thombs et al., 2010). For this study, a total score of items 1-14 was used to 
measure depressive symptoms to avoid the influence of other treatment-related symptoms. 
Higher total scores of the 14 items indicate more severe depressive symptoms. Item 16 from 
BDI-II (changes in sleep pattern) was used to measure the severity of changes in sleep pattern.  
The PAOFI, is a 33-item self-report measure of subjective perceived cognitive 
impairment, rated on a 6-point scale range from 0 (almost never) to 5 (almost always) (Chelune 
et al., 1986). The PAOFI has been used in studies among women with breast cancer (Ganz et al., 
2014; Pullens, De Vries, & Roukema, 2010), with evidence for construct validity and reliability 
(Bell, Terhorst, & Bender, 2013). Higher average scores indicate poorer perceived functioning.  
The BCPT is a self-report measure of symptoms related to endocrine therapy comprised 
of subscales including cognitive symptoms, musculoskeletal pain, vasomotor symptoms, 
gastrointestinal symptoms, dyspareunia, bladder control, weight concerns, and gynecologic 
symptoms (Stanton, Bernaards, & Ganz, 2005). It has 42 items rated on a 5-point Likert scale, 
from 0 (not at all) to 4 (extremely). Higher scores of each item indicate greater symptom 
severity.  Only 41 BCPT items were used in this study, item 33 (tendency to take naps) was 
deleted for the analysis because of its strong correlations with fatigue and depressive symptoms. 
1.6.4.3 Genotype data 
Among participants who provided a blood sample (n=283), genomic deoxyribonucleic acid (DNA) 
was extracted from white blood cells by the simple salting-out method (Miller, Dykes, & Polesky, 
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1988). If blood was unavailable, DNA was extracted from saliva using prepIT•L2P (Genotek, 
2016). Samples were genotyped using the iPLEX MassArray platform with proven accuracy 
(>99.7% concordance rate).  As shown in Table 1, a total of 51 functional SNPs were selected for 
analysis. To control quality for genetic association analysis, SNPs with call rates of <95% or 
Hardy-Weinberg Equilibrium p-values of <.05 were excluded. 
1.6.5  Data analysis 
1.6.5.1 Descriptive statistics 
Data was analyzed using SAS 9.4 (SAS Institute, North Carolina). Given a variable’s level of 
measurement and data distribution, appropriate descriptive analyses were used to summarize the 
demographic, clinical, genetic characteristics and the prevalence of each symptom and the mean 
symptom severity score.  
To describe central tendency for ratio variables (e.g., age, education level), mean and 
standard deviation (SD) were used for normally distributed variables. If the normality 
assumption was not satisfied, median and interquartile range (IQR) were used. For describing 
nominal variables, we used frequency and percentage and the mode to summarize central 
tendency and the range to summarize the variability. We used symptom severity score to 
describe symptoms. The symptom severity score was calculated as the mean of the symptom 
score. 
1.6.5.2 Data screening procedures 
Outliers were assessed by frequency distribution, z-scores and the Mahalanobis Distance. 
For continuous variables, univariate outliers can be identified by transforming the data into z-
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scores. If z-score is greater than +3.29 or less than -3.29, a case can be considered as a univariate 
outlier (Tabachnick, Fidell, & Ullman, 2007). Multivariate outliers can be identified using 
Mahalanobis Distance (Mahalanobis, 1936), if the value for the Mahalanobis distance was 
significant beyond p<0.001. For categorical variables, we looked at frequency distribution and 
examined whether there were sparsely populated categories. 
For the treatment of missing data, first, we explored the data and checked the amount of 
missing data by looking at the percentage of cases having any missing data, distribution of 
univariate, multivariate, and bounded missing data. Then, the pattern of missing data was checked 
by exploring the occurrence of missing data by variable and by participant and their combination 
at each time point and over time points. From these results, we could identify univariate missing 
or multivariate missing, missing completely at random (MCAR), missing at random (MAR) or 
missing not at random. If an observation was missing not at random, and if that participant was 
missing more than 50% of items within one symptom scale, we deleted that participant. For cases 
of MAR and MCAR, multiple imputation was used to handle missing data for EFA. Missing values 
were estimated multiple times based on the amount of the missing data. Estimates from analyses 
from each completed dataset were pooled into one estimate.   
Group-based trajectory modeling (GBTM) handles missing data by fitting the model using 
maximum likelihood estimation. Data were assumed MAR for GBTM. Since we have up to four 
time points for each participant. We included those who had data collected at two or more times, 
and exclude those with fewer than two. 
Multiple underlying assumptions were checked before the analysis, such as independence, 
linearity, multicollinearity, and homoscedasticity. Independence is a primarily a design issue. To 
check independence between participants, we can go back to the study design and check whether 
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participants are independent of each other. If data were collected from family members or in a time 
trend, the assumption of independence was violated. 
Linearity was assessed by inspecting simple bivariate scatterplots of predictors and 
dependent variables. Multicollinearity occurs when variables are highly correlated (Hahs-Vaughn, 
2016). Tolerance test or variance inflation factors (VIF) were used to assess for multicollinearity. 
The recommended maximum VIF value is 5 (Rogerson, 2001). The assumption of 
homoscedasticity is a necessary condition for the assumption of normality (Tabachnick, Fidell, & 
Osterlind, 2001). This assumption was examined by scatterplots of variables. Points are about the 
same distance from the line in a consistent pattern suggest variances are constant. If 
homoscedasticity was not found, then transformations (variance of stabilizing) of variables were 
considered. 
1.6.5.3 Aim-specific data analysis strategies 
Aim 1: EFA was conducted using principal axis factoring (PAF) as the extraction method with 
the promax rotation method to identify symptom clusters from the 48 symptoms, as it is expected 
that factors would be correlated (Henoch, Ploner, & Tishelman, 2009). Compared with other 
extraction methods, PAF is a more conceptually appropriate and is the commonly used method 
to identify symptom clusters without normal distribution assumption of the symptom data 
(Skerman, Yates, & Battistutta, 2009). To increase clinical significance and have sufficient 
variation for EFA, symptoms with a prevalence less than 20% were excluded from the analysis. 
Reliability estimates, the internal consistency was examined among symptoms with a prevalence 
greater than 20% using Cronbach’s α. To measure sampling adequacy for exploratory factor 
analysis, the Kaiser-Meyer-Olkin (KMO) statistics, and Bartlett’s test of sphericity were 
computed. KMO test measures the sampling adequacy of each variable by calculating the 
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proportion of variance among variables, with desired value higher than 0.80 (Cerny & Kaiser, 
1977). Bartlett’s test of sphericity measures whether correlation matrix for the data is an identity 
matrix (Tabachnick & Fidell, 2001). If the p-value from the Bartlett’s test of sphericity was less 
than 0.05, it indicated that the dataset was suitable for factor analysis. The eigenvalues, the scree 
plots, and amount of variance explained for each factor, or cluster from the EFA were used to 
determine the number of extracted clusters. The minimum factor loading of an item considered 
meaningful in this analysis was 0.40 (Browne, 2001). To be define a symptom cluster, at least 
two symptoms must load together, the Cronbach α must be greater than 0.60, and the symptom-
total correlations must greater than 0.25 (Ferketich, 1991). Separate EFAs were performed at the 
four specific time points. By conducting EFAs at four time points, we were able to examine the 
stability of symptom clusters from pre-adjuvant therapy until 18 months of adjuvant therapy. 
Symptoms were considered stable when they present in the same symptom cluster at least three 
time points.  
Aim 2: Group-based multi-trajectory modeling was used to classify women with breast 
cancer into subgroups with “similar” psychological symptom cluster trajectories over the 18-
month course of adjuvant therapy. The SAS macro PROC TRAJ (Jones, 2014) was used to 
perform this analysis. First, based on our prior knowledge of symptom clusters trajectory studies 
(Avis, Levine, Case, Naftalis, & Van Zee, 2015; Donovan et al., 2013), models with two to five 
subgroups will be fitted. To identify the optimal number of subgroups among trajectory models, 
we used the following the criteria for model selection: (1) biggest Bayesian Information 
Criterion (BIC) value, (2) average posterior probabilities (AvePP) of class membership should 
exceed 0.7 for all subgroups, (3) the odds of correct classification should exceed 5 for all 
subgroups, and (4) close correspondence between the estimated probability of group membership 
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and the proportion classified in that group (Nagin & Odgers, 2010). Maximum 
likelihood estimation was used to estimate model parameters. The parameters of the 
unconditional multi-trajectory modeling included the probability of membership in each 
subgroup’s trajectory, and the regression coefficients of each subgroup’s trajectory (i.e., 
intercept, linear, quadratic). The significance level was at 0.05.  
Aim 3: Binary logistic regression analysis was used to explore the association between 
genotypic and phenotypic predictors and predicted psychological symptom cluster membership 
separately. Assumptions of independence, linearity in the logit for continuous variables, 
nonadditivity and no serious multicollinearity were checked first in order to perform multinomial 
logistic regression. Hardy-Weinberg equilibrium and linkage disequilibrium were assessed by 
PLINK 1.0.7. For each SNP, additive, dominant and recessive models were assessed in the 
model. The genetic model with the lowest p-value obtained from the three genetic association 
tests were selected for each SNP.   
The phenotypic characteristics of age, marital status, employment status, education, stage 
of disease and whether chemotherapy was received were evaluated as potential predictor 
variables. Univariate logistic regression analyses were first be used to identify possible 
phenotypic predictor variables with those predictor variables having p < 0.10 be included in the 
multivariable model.  
To explore the genetic associations with predicted trajectory subgroup membership, a 
total of 51 SNPs among the 6 candidate genes that passed all quality control filters were included 
in the analyses. Bivariate analyses were performed for each SNPs. Possible SNPs with p < 0.10 
identified in the bivariate analyses were evaluated in the final model with the control of 
phenotypic characteristics. Each significant SNP adjusted for phenotypic characteristics were 
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reported separately in the final presentation of the results. Covariate-adjusted odds ratios (ORs) 
and 95% confidence interval were reported to estimate the magnitude and precision of the 
association between predictor variables and subgroup membership. For all the phenotypic and 
genotypic models, p < 0.05/i (i is the number of subgroups) was interpreted as significant, using 
Bonferroni correction for post-hoc pairwise contrasts. Chi-square goodness of fit test and 
residual analysis were used to assess the model fit of the logistic regression model. 
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2.0 SUMMARY OF STUDY 
There are significant gaps in our understanding of the psychological symptom cluster 
experienced by women with breast cancer receiving adjuvant therapy with regard to the 
following issues: (1) it is not clear what the stable core symptoms are comprising the 
psychological symptom cluster and their trajectories experienced by women with breast cancer 
during adjuvant therapy, especially for long-term AI therapy; (2) it is not clear whether distinct 
subgroups of women with breast cancer exist based on the severity of the psychological 
symptom cluster they experience during adjuvant therapy; and (3) it is not clear whether there 
are demographic (i.e., age, education, employment status, marital status), clinical (i.e., disease 
stage, whether received chemotherapy) or genotypic (i.e., variation in polymorphisms) pre-
therapy factors that may be associated with predicting subgroup membership within the 
psychological symptom cluster based on the symptom experience during adjuvant therapy. 
Based on the gaps identified about the psychological symptom cluster, this dissertation 
research has (1) identified symptom clusters at four time points from baseline (pre-adjuvant 
therapy) to 18 months of adjuvant therapy in postmenopausal women with early stage breast 
cancer; (2) identified distinct subgroups of postmenopausal women with early stage breast cancer 
based on the severity of the stable symptoms within the psychoneurological symptom cluster 
from baseline (pre-adjuvant therapy) to the first 18 months of adjuvant therapy; and (3) explored 
demographic and clinical factors (age, marital status, education level, treatment characteristics, 
stage of disease) and genotypic factors (variations in polymorphisms related to HPA axis 
function) associated with the subgroup membership of the trajectories of the psychological 
symptom cluster. In regard to genetic factors, the current study focused on genes and 
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polymorphisms known to regulate activity of the HPA axis in light of evidence that 
dysregulation of this system and associated inflammation may contribute to the experience of 
psychoneurological symptoms.  
Three manuscripts were developed related to this dissertation project during the course of 
PhD training. We conducted a study to identify core symptoms of the psychological symptom 
cluster from the first two manuscripts. In the first manuscript, entitled “Impact of chemotherapy 
on symptoms and symptom clusters in postmenopausal women with breast cancer prior to 
aromatase inhibitor therapy”, we identified and compared differences in symptom and symptom 
clusters between postmenopausal women with early stage breast cancer who did and did not 
receive chemotherapy prior to AI therapy. This manuscript was submitted to the Journal of 
Clinical Nursing. In this study, seven distinct symptom clusters were revealed in both groups prior 
to AI therapy: cognitive, musculoskeletal, psychological, vasomotor, weight, sexual and urinary, 
with additional gastrointestinal symptom cluster been identified in women who received 
chemotherapy. Women who received chemotherapy prior to AI therapy experienced higher 
severity of symptoms and greater number of symptom clusters than women who did not receive 
chemotherapy. This study showed the existence of the psychological symptom cluster and 
provided the foundation for our investigation of the psychological symptom cluster and 
examination of the stability of this symptom cluster over the first 18 months of adjuvant therapy. 
The second manuscript, entitled “Stability of symptom clusters in women with breast cancer 
during the first 18 months of adjuvant therapy”, was submitted to the Journal of Pain and Symptom 
Management. This article reported on the identification and evaluation of the changes in symptom 
clusters in women with breast cancer from pre-adjuvant therapy to 18 months after initiation of 
adjuvant therapy. Most symptom clusters (i.e., psychological, neurocognitive, weight, 
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musculoskeletal, vasomotor, urinary, and sexual) existed before adjuvant therapy and were 
relatively stable through the first 18 months of therapy. Core stable symptoms (i.e., fatigue, 
depressive symptoms, and anxiety) within the psychological symptom cluster were also identified 
in this manuscript. To better understand the inter-individual differences of the psychological 
symptom cluster, we identified subgroups of women who experienced higher severity of the 
psychological symptom cluster during adjuvant therapy and explored associations between 
demographic and clinical characteristics and variation in genetic polymorphisms related to HPA 
axis function and predicted symptom subgroup membership based on multi-trajectory modeling. 
Results of this analysis were reported in the third manuscript, “Genes involved in the HPA axis 
and a symptom cluster of fatigue, depressive symptoms and anxiety in women with breast cancer 
during 18 months of systemic adjuvant therapy”. This manuscript was submitted to Psycho-
oncology. Two distinct symptom subgroups (“all low” and “all high”) were identified based on the 
trajectories of fatigue, depressive symptoms and anxiety. The “all low” subgroup had stable low 
severity of fatigue and depressive symptoms and a linear decreasing pattern for anxiety over time. 
The “all high” subgroup had stable high severity of fatigue and depressive symptoms and a 
quadratic pattern for anxiety over time. Younger age, less education and treatment with 
chemotherapy were associated with greater likelihood of being in the high symptom subgroup. 
Polymorphic variation in genes related to the HPA axis (i.e., FKBP5 rs9394309, NR3C2 rs5525, 
CRHR1 rs12944712) also predicted risk for high severity of psychological symptoms.   
In summary, this dissertation project has contributed to filling several gaps in the literature 
about the psychological symptom cluster among postmenopausal women with early stage breast 
cancer. Stable symptoms (i.e., fatigue, depressive symptoms, anxiety) clustered within the 
psychological symptom cluster and their trajectories during 18 months of adjuvant therapy were 
40 
identified. Subgroups of women who have higher severity of the psychological symptoms were 
identified based on symptoms trajectories. Phenotypic and genotypic predictors related to the 
subgroup membership let us better understand the inter-individual differences of symptoms 
experienced by women with breast cancer.  Results of this study will help healthcare providers 
screen women with breast cancer and identify those who are at increased risk for psychological 
symptoms, facilitating the development of preemptive and individualized interventions to manage 
symptoms and improve quality of life during cancer treatment. 
2.1 CHANGES TO PROPOSAL 
Several changes were made to this dissertation proposal after the comprehensive examination 
and dissertation overview and have been approved by all committee members. The detailed 
information about the aforementioned changes is listed below.  
2.1.1  Changes to final gene list 
Due to budgetary limitations and the design of iPlex, we deleted 11 SNPs from the original gene 
list. Table 4 contains the final list of SNPs for candidate gene analysis.  
Table 4 Final List of  SNPs for Candidate Gene Analysis 
Gene SNPs 
CRHR2 (Corticotropin Releasing 
Hormone Receptor 2) 
rs8192496 
rs255098 
rs3779250 
NR3C1 (Glucocorticoid receptor) rs41423247 
rs258747 
rs10482605 
41 
rs180044 
rs6191 
rs258813 
rs33388 
rs10052957 
rs6198 
rs6189 
rs6190 
FKBP5 (FK506-binding protein 5) rs1360780 
rs3800373 
rs9470080 
rs4713916 
rs9296158 
rs9394309 
rs3777747 
rs17542466 
rs2766533 
rs9380526 
rs9394314 
rs2817032 
rs2817040 
rs7753746 
rs4713902 
rs774826 
rs7757037 
NR3C2 (mineralocorticoid receptor) rs5525 
rs4835488 
rs10213471 
rs2070951 
CRHB (Corticotropin releasing 
hormone binding protein) 
rs10473984 
rs7718461 
rs1875999 
CRHR1 (Corticotropin Releasing 
Hormone Receptor 1) 
rs17689918 
rs4458044 
rs242924 
rs1768996 
rs12944712 
rs12938031 
rs4792887 
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rs1396862 
rs17763104 
rs110402 
rs242948 
rs1876828 
rs17689882 
rs12936511 
rs242941 
2.1.2  Additional analysis of symptom clusters 
Originally, symptom clusters were identified in a mixed population of two cohorts of women. 
Based on suggestions from the dissertation committee members, factor analysis was performed 
separately for women in ChemoAnast and AnastOnly groups at each time point. Due to the limited 
sample size, the "comparisons" that were accomplished over time and between the two treatment 
cohorts are purely descriptive. Results showed that at baseline and 18 months, fatigue and changes 
in sleep patterns clustered together with other psychological symptoms in AnastOnly group. These 
two symptoms stood out as a unique symptom cluster in ChemoAnast group. The GI symptom 
cluster was identified at 6 months in ChemoAnast group only. At 12 months, fatigue and 
depressive symptoms clustered with musculoskeletal symptoms in AnastOnly group. Separate 
exploratory factor analyses for each cohort allowed us to better understand different experience of 
symptom clusters between the two treatment groups and gave us insights that the appearance of 
the GI symptom cluster was not related to AI therapy. 
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2.2 STUDY STREGTH AND LIMITATIONS 
This study examined a comprehensive list of symptoms which may be experienced by women 
with breast cancer. Several previous studies have examined symptom clusters comprised of pre-
determined set of symptoms (Denieffe et al., 2014; Ho et al., 2015; Sanford et al., 2014). 
However, given the fact that symptoms may change over time and that different symptoms can 
be associated with different treatments, some important symptoms may have been overlooked 
using this approach. The advantage of presenting participants with a more comprehensive list of 
possible reportable symptoms reduces the potential for selection bias. Our approach is more 
empirically-based and reliable because it takes into consideration a comprehensive list of 
symptoms that may be experienced. In addition, this is the first study to evaluate changes in 
symptom clusters among women with breast cancer from pre-adjuvant therapy up to 18 months 
after starting adjuvant therapy. Our longitudinal study allows us better understand the changes in 
symptom clusters over time during chemotherapy and AI therapy. Few studies have included the 
baseline (pre-adjuvant therapy) time point. This is the first symptom cluster study to include the 
pre-adjuvant therapy time point among women with breast cancer. Having this baseline 
assessment helped us identify whether the symptom clusters existed before adjuvant therapy or 
appeared after therapy. Lastly, this is the first study to evaluate variation in genes and 
polymorphisms related to the HPA axis and the severity of the psychological symptom cluster 
over time among women with breast cancer. Variation in genes and polymorphisms related to the 
HPA axis can be used as clinical biomarkers to identify patients who may be at greater risk of 
more severe fatigue, depressive symptoms and anxiety.  
There are some important limitations to acknowledge in this study. First, 97.0% of the 
women in this study were Caucasian. Thus, the generalizability of the study results is limited due 
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to the racial homogeneity of the sample. Secondly, the recommended sample size in EFA is at least 
300, based on the criteria “100 = poor, 200 = fair, 300 = good, 500 = very good, ≥1000 = excellent 
(MacCallum et al., 1999). Our sample (n=354) was sufficient to conduct the factor analysis at 
baseline and 6 months (n=288); however, we lost some precision to conduct EFA at the later 
follow-up time points due to study attrition (n=205 at 12 months, n=156 at 18 months). 
Additionally, our sample was not of sufficient size to accommodate multiple testing of the 
associations between polymorphisms in the HPA axis related genes and predicted subgroup 
membership of the psychological symptom cluster. However, this exploratory study does lay the 
initial groundwork for future larger scale studies to confirm the relationships between phenotypic 
and genotypic predictors and the predicted subgroup membership. Future research which includes 
a larger more diverse study population is needed confirm the findings of this study. Thirdly, the 
dimensions of symptoms (i.e., occurrence, severity, and distress) can influence the results of the 
symptom cluster. We identified symptom clusters using only symptom severity scores. One study 
showed that different types of symptom clusters may emerge when using severity versus distress 
as the dimension evaluated (Suwisith et al., 2008). Other studies have provided evidence that using 
occurrence and severity ratings would produce similar numbers and types of symptom clusters 
(Kim et al., 2009; Sullivan et al., 2017). Therefore, future research is needed to examine different 
dimensions of the symptoms when identifying symptom clusters. Lastly, other predisposing 
factors, such as demographic and clinical characteristics, personality, general health, menopausal 
status, and duration of menopause can influence the severity of symptoms among women with 
breast cancer (Bower et al., 2019; Lockefeer & De Vries, 2013; Mazor et al., 2018). Future research 
is needed to compare the symptom experience of healthy women and consider the influence of 
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personality, general health, menopausal status and duration of menopause on the symptom 
experience of women with breast cancer. 
2.3 FUTURE DIRECTIONS 
This dissertation project has filled gaps in the literature about the psychological symptom cluster 
among women with breast cancer receiving adjuvant therapy. However, many questions remain 
unanswered in the symptom cluster research among oncology patients. The following areas still 
warrant consideration in future research: (1) study population; (2) assessment of symptom clusters; 
(3) methods to identify symptom cluster; (4) mechanisms underlying symptom clusters; and (5)
individual symptom variability and personalized symptom management. 
2.3.1  Study population 
It is unknown whether symptom clusters differ depending upon on the type of cancer diagnosis, 
stage of cancer and types of cancer treatment received. We still need to understand whether 
symptom clusters are affected by disease or treatment. Therefore, future studies can identify 
symptom clusters and symptom cluster trajectories across cancer diagnoses and cancer treatment. 
For example, study is needed to evaluate symptom clusters among women with ovarian cancer and 
breast cancer. A study can be conducted among a mix of patients with different cancers to evaluate 
differences or similarities in symptom clusters during chemotherapy. In addition, with the 
significant progress of immunotherapy and targeted therapies in the past decade, research is needed 
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to assess and manage symptoms and symptom clusters associated with immunotherapy or targeted 
therapies used in the treatment of cancer.  
2.3.2  Assessment of symptom clusters 
To identify symptom clusters from a comprehensive symptom assessment, additional research is 
needed to determine the optimal number and types of symptoms to assess for oncology patients. 
Research is needed to summarize and identify the core symptoms to assess for each types of 
cancer. Even though some assessment instruments contain a broad range of symptoms, some 
symptoms can still be overlooked in each instrument. For example, the BCPT symptom checklist 
assesses 42 symptoms (Stanton et al., 2005); however, it does not include fatigue, anxiety, 
general pain, and depressive symptoms. The Memorial Symptom Assessment Scale evaluates 32 
symptoms on four dimensions (Portenoy et al., 1994); however, it does not include weight gain 
and hot flashes. These overlooked symptoms are commonly experienced and important 
symptoms to assess for some types of cancer patients (i.e., breast cancer). 
In addition, symptoms are multidimensional with different frequencies, and levels of 
intensity and distress. This study only examined the existence and composition of symptom 
clusters based on symptom severity scores. In addition to symptom severity, other symptom 
dimensions (i.e., occurrence, distress) can be used to characterize symptoms.  
To date, most symptom cluster research collected data from self-reported symptom 
instruments. Few studies have evaluated symptom clusters from electronic health records. Further 
studies are needed to confirm these symptom clusters in a larger population, possibly using 
electronic health records. Natural language processing and text mining can be used to collect 
patient-authored symptom data from electronic health records (Dreisbach, Koleck, Bourne, & 
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Bakken, 2019). Electronic health records will allow us to assess a broad range of symptoms with 
more symptom assessment time points. Wearable devices and smart phone technology can also be 
used to collect real-time data and better evaluate the dynamic changes of symptoms.  
2.3.3  Methods to identify symptom clusters 
In addition to EFA and GBTM, other novel machine learning methods can be used to identify 
different dimensions of symptom clusters in future studies. For example, network analysis could 
be used to identify co-occurring symptoms and symptom clusters based on different dimensions 
of specific symptoms (Papachristou et al., 2019). Bayesian network analysis can be used to 
identify causal relationships between co-occurring symptoms and determine the “trigger” 
symptom (Xu et al., 2018). Other clustering algorithms (i.e., k-means, Hierarchical 
Agglomerative Clustering, Spectral-Clustering) can be used to identify symptom clusters and 
subgroups of patients based on symptom experience (Papachristou et al., 2016). 
2.3.4  Mechanisms that underlie symptom clusters 
This study explored the correlation between variation in genes and polymorphisms related to HPA 
axis and the experience of the psychological symptom cluster among women with early-stage 
breast cancer. Genetic variation in HPA axis sheds light on the mechanisms underlying the 
psychological symptoms, which suggests that dysregulation of the HPA axis and glucocorticoid 
receptor sensitivity may play a role in fatigue, depressive symptoms, and anxiety. To advance our 
understanding of the dysregulation of the HPA axis underlying the psychological symptom cluster, 
longitudinal studies are needed to examine biomarkers related to the function of the HPA axis and 
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the neuroendocrine system. Future research is needed to evaluate the underlying genetic and 
epigenetic mechanism for the psychological symptom cluster. For example, studies can examine 
how epigenetic changes of the genes related to the HPA axis and GR receptors contribute to 
psychological symptoms among cancer patients during cancer diagnosis and cancer treatment 
trajectory. Thus, pharmacological or psychosocial interventions that target the functions of the 
HPA axis could be developed to further manage the symptoms. 
In addition to the dysregulation of the HPA axis, research is needed to explore other 
possible common mechanisms of different symptom clusters, such as changes in the central 
nervous system, circadian rhythm disruption, sympathetic nervous system activation, tissue 
damage and their interaction with inflammation and the immune system. It is also interesting to 
identify whether common mechanisms exist across different symptom clusters (i.e., psychological, 
hormonal, GI, and cognitive).
2.3.5  Individual symptom variability and personalized symptom management 
Results of this study emphasize the need for personalized symptom management. Genetic features, 
demographic and clinical characteristics can be used to personalize the prediction of the risk for 
psychological symptoms among women with breast cancer. Future studies are needed to examine 
more molecular, genetic, demographic, clinical and behavioral factors (i.e., acute and chronic 
stress during cancer treatment, family history, early life trauma, physical activity, and personality) 
and the severity of symptom clusters, not only limited to the psychological symptom cluster. The 
integration of big data (i.e., phenotypic, genotypic and molecular data) and machine learning with 
predictive models can help us identify and predict who may have a higher risk of developing severe 
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symptom profiles based on predisposing and precipitating factors. Therefore, personalized 
interventions can be developed to reduce patients’ symptom burden effectively. 
50 
3.0 DATA-BASED MANUCRIPT 
3.1 IMPACT OF CHEMOTHERAPY ON SYMPTOMS AND SYMPTOM CLUSTERS IN 
POSTMENOPAUSAL WOMEN WITH BREAST CANCER PRIOR TO 
AROMARASE INHIBITOR THERAPY 
3.1.1  Abstract 
Women with breast cancer often experience multiple concurrent symptoms during aromatase 
inhibitor (AI) therapy. The burden of symptoms prior to AI are associated with nonadherence to 
cancer treatment. To date, few studies have comprehensively explored the symptoms and symptom 
clusters occurring prior to AI therapy. The purpose of this study was to examine and compare the 
differences in symptoms and symptom clusters between postmenopausal women with early stage 
breast cancer who did and did not receive chemotherapy prior to AI therapy. This was a secondary 
analysis of a prospective repeated measures study. The sample comprised postmenopausal women 
(N=339) with breast cancer who would receive AI therapy with or without chemotherapy. We 
collected information on 48 symptoms after surgery or chemotherapy but before AI therapy from 
different symptom assessment tools. Mann-Whitney U tests were used to compare the differences 
in the severity of symptoms between groups. Exploratory factor analysis (EFA) was conducted to 
determine symptom clusters. Overall, this study indicates the presence of symptoms among 
women with breast cancer prior to AI therapy, with higher severity of symptoms and greater 
number of symptom clusters for women who received chemotherapy. Results showed that the most 
severe symptoms among women with breast cancer prior to AI therapy were: breast sensitivity, 
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unhappy with the appearance of my body, general aches and pain, joint pain and muscle stiffness. 
Women who received chemotherapy prior to AI therapy experienced significantly higher severity 
of 22 symptoms than women who did not receive chemotherapy. Through EFA seven distinct 
symptom clusters were revealed in both groups: cognitive, musculoskeletal, psychological, 
vasomotor, weight, sexual and urinary, with an additional gastrointestinal symptom cluster 
identified in women who received chemotherapy. Nurses should assess and be aware of symptoms 
and symptom clusters existed prior to AI therapy and manage them in advance. 
3.1.2  Introduction 
Approximately 75% of women with breast cancer have estrogen receptor (ER) positive 
disease. A minimum of 5 years of aromatase inhibitor (AI) therapy is recommended for 
postmenopausal women with ER-positive early-stage breast cancer with or without chemotherapy 
(Burstein, Lacchetti, & Griggs, 2016). During AI therapy, 94% of women experience multiple 
concurrent symptoms or adverse effects, such as fatigue, hot flashes, insomnia, cognitive problems 
and musculoskeletal pain (Aiello Bowles et al., 2012; Garreau et al., 2006). One third of women 
with breast cancer do not adhere to AI therapy, primarily because of symptoms they experience 
during treatment (Henry et al., 2012). It has been suggested that some of these symptoms may be 
present prior to AI therapy rather than be a result of this treatment (Kidwell et al., 2014). 
Furthermore, evidence suggests that pre-treatment symptoms positively symptom burden among 
breast cancer patients during cancer treatment (Liu et al., 2009), and relates to the discontinuation 
of AI treatment (Kidwell et al., 2014). Thus, identifying symptoms present prior to AI therapy may 
be helpful in managing symptoms in advance, which is a critical step in improving symptom 
experience during treatment and adherence to AI therapy. 
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3.1.3  Background 
There has been growing interest in symptom cluster research within the last 15 years, since 
patients usually experience multiple co-occurring symptoms, also known as symptom clusters, 
during and after treatment, or due to the disease itself (Nguyen et al., 2011). According to 
Miaskowski (2016), “a priori” and “de novo” are the two common approaches to conceptualizing 
symptom clusters. A prior studies of women with breast cancer identify different subgroups of 
women based on predetermined symptoms (Sanford et al., 2014; Ho et al., 2015). Whereas, de 
novo studies administer several symptom assessments and identify different clusters of 
symptoms that develop during the treatment course (Browall, Brandberg, Nasic, Rydberg, Bergh, 
Rydén, Xie, Eriksson, & Wengström, 2017; Roiland & Heidrich, 2011). Most symptom cluster 
studies have evaluated symptom clusters during the short time treatment period (i.e., 
chemotherapy or radiation therapy) among women with breast cancer (Albusoul, Berger, Gay, 
Janson, & Lee, 2017; Hsu et al., 2017; Sullivan et al., 2018). To date, few studies have evaluated 
symptom clusters prior to AI therapy. One study evaluated a symptom cluster of sleep quality, 
concentration, fatigue, anxiety and depressive symptom among women with breast cancer prior 
to AI initiation (Kidwell et al., 2014). Another study comprehensively assessed symptoms 
among both pre- and postmenopausal women with breast cancer prior to the initiation of 
tamoxifen and AI therapy (Ganz et al., 2016). These studies either evaluated symptom clusters 
from limited number of predetermined symptoms or only evaluated the severity of separate 
symptoms separately prior to AI therapy among women with breast cancer. None of them 
compared the symptom and symptom cluster experiences among postmenopausal women with 
early stage breast cancer who did and did not receive chemotherapy prior to AI therapy. The 
severity of pre-treatment symptoms may vary from individual to individual, influenced by 
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previous treatment received and different demographic characteristics, physical health, and 
disease status. It is important to identify women who are at risk for severe symptom profiles and 
manage symptoms in advance. It is possible that women who received chemotherapy prior to AI 
therapy may have severe symptom profiles than women who did not receive chemotherapy. 
Therefore, the objective of this study was to measure a broad scope of symptoms to access and 
compare the severity of pre-treatment symptoms and the composition and type of symptom 
clusters between postmenopausal women with early stage breast cancer who did and did not 
receive chemotherapy prior to AI therapy.  
3.1.4  Methods 
3.1.4.1 Study design 
This was a secondary analysis of symptom data from an Institutional Review Board approved 
prospective repeated measures study of cognitive function in postmenopausal women receiving 
the AI, anastrozole, for early stage breast cancer (R01-CA107408) (Bender et al., 2015). The 
current investigation included two cohorts of women with early stage breast cancer who had 
completed surgery: women prescribed anastrozole therapy only (AnastOnly Group) and 
chemotherapy and anastrozole therapy (ChemoAnast Group).  
3.1.4.2 Setting and sample 
A total of 339 women with breast cancer were enrolled in the study. Women with breast cancer 
were recruited between 2005 and 2015 from the Comprehensive Breast Care Program of the 
UPMC Hillman Cancer Institute from Magee-Women's Hospital, Hillman Cancer Center, and 
Shadyside Hospital. Inclusion criteria were women who were: (1) newly diagnosed with stage I, 
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II or IIIA breast cancer; (2) ≤75 years of age; (3) postmenopausal; (4) scheduled to receive 
chemotherapy plus anastrozole or anastrozole only as post-surgical follow-up therapy; and (5) able 
to speak and read English; and (6) who had completed a minimum of 8 years of education. 
Exclusion criteria included: (1) self-report of hospitalization for psychiatric illness within the last 
2 years; (2) prior diagnosis of neurologic illness, such as stroke, multiple sclerosis, dementia 
syndrome, or Parkinson’s disease or of HIV-related dementia or chronic fatigue syndrome; 3) prior 
diagnosis of cancer; or 4) clinical evidence of distant metastases.  
3.1.4.3 Procedures 
Following written informed consent, women in the ChemoAnast group completed a 
demographic, clinical characteristics and symptom assessment at enrollment after surgery but 
before chemotherapy (T0), and symptom data were collected again after chemotherapy but 
before the initiation of AI therapy (T1). Women in the AnastOnly group completed a 
demographic, clinical characteristics and symptom assessment at enrollment after surgery and 
before the initiation of AI therapy (T0). The study flow diagram is displayed in Figure 3. For this 
study, we compared the severity of symptoms and number of types of symptom clusters at T0 for 
AnastOnly group and T1 for ChemoAnast group.  
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Figure 3 Study Flow Diagram 
3.1.4.4 Measurement 
Socio-demographic information (e.g., age, race, education level etc.) and clinical characteristics 
(e.g., stage of disease, treatment etc.) were recorded at baseline.  
Of the 48 symptoms evaluated, 42 symptoms were assessed with the Breast Cancer 
Prevention Trial (BCPT) Symptom Checklist (Stanton et al., 2005). Since the BCPT symptom 
checklist did not include fatigue, anxiety, general pain, depressive symptoms, changes in sleep 
patterns and perceived cognitive impairment, we assessed 6 more symptoms using the Profile of 
Mood States (POMS; fatigue, anxiety) (McNair et al., 1992), Brief Pain Inventory-Short Form 
(BPI; pain) (Cleeland & Ryan, 1994), Beck Depression Inventory-II (BDI-II; depressive 
symptoms) (Beck et al., 1996), and Patient’s Assessment of Own Functioning (PAOFI; perceived 
cognitive ability) (Chelune et al., 1986).  
The BCPT is a self-report measure of symptoms related to endocrine therapy comprised of 
subscales including cognitive symptoms, musculoskeletal pain, vasomotor symptoms, 
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gastrointestinal symptoms, dyspareunia, bladder control, weight concerns, gynecologic symptoms 
(Stanton et al., 2005). It has 42 items rated on a 5-point Likert scale, from 0 (not at all) to 4 
(extremely). The Cronbach's alpha was 0.895 in this study. 
Two subscales of the POMS (Fatigue/Inertia subscale and Tension/Anxiety subscale) were 
used to measure fatigue and anxiety. POMS is a self-report measure of mood states, with 65-items 
rated on a 5-point Likert scale format from 0 (not at all) to 4 (extremely) (McNair et al., 1992). 
POMS-Fatigue/Inertia subscale has 7 items, the Cronbach's alpha in this study was 0.945. POMS-
Tension/Anxiety subscale has 9 items, the Cronbach's alpha in this study was 0.799.  
Pain was measured with the BPI-short form which consists of 9 items related to pain 
intensity, pain relief treatment or medication and pain interference (Cleeland & Ryan, 1994). The 
Cronbach's alpha was 0.915 in this study. For this study, 4 items related to pain severity were used. 
The BDI-II is a 21-item, self-report measure in which depressive symptom severity is rated 
on a 4-point Likert scale from 0 (no symptom) to 3 (severe symptom) (Beck et al., 1996). The 
Cronbach's alpha was 0.838 in this study. Higher average scores of 21 items indicate more severe 
depressive symptomatology. For this study, a total score of items 1-14 (cognitive/affective scores) 
was used to measure depressive symptoms to avoid the influence of other treatment related 
symptoms. Higher total scores of the 14 items indicate more severe depressive symptoms. Item 16 
from BDI-II (changes in sleep pattern) was used to measure the severity of changes in sleep pattern. 
The PAOFI, a 33-item self-report measure of subjective perceived cognitive impairment, 
is rated on a 6-point scale range from 0 (almost never) to 5 (almost always) (Chelune et al., 1986). 
The Cronbach's alpha was 0.916 in this study. Higher average score (range 0-5) of 33 items 
indicate poorer perceived functioning.  
Symptom severity score was calculated as the mean of the symptom scores of participants 
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who experienced this symptom. To standardize the scaling of symptom severity scores among the 
instruments used, the symptom severity scores were transformed to a 0–100 scale. Following 
formula was used for our data transformation: X’=[X-min(X)]/ [max(X)-min(X)] × 100, where X 
is the particular symptom in its original scaling. 
3.1.4.5 Statistical analysis 
Data were analyzed using IBM® SPSS® Statistics Version 25 (IBM Corp., Armonk, NY). Data 
were first screened for missing data (amount and pattern), outliers, normality, etc. Based on the 
patterns of missing data, appropriate strategies (i.e., multiple imputations) were used. Given a 
variable’s level of measurement and data distribution, student t test and chi-square test statistics 
were used to summarize and compare the demographic and clinical characteristics between groups. 
Since the symptom data did not follow a normal distribution, Mann-Whitney U tests were used to 
compare the mean symptom severity score by treatment groups. 
To identify symptom clusters from the 48 possible individual symptoms, exploratory factor 
analysis (EFA) was conducted using principal axis factoring as the extraction method. The promax 
rotation method was used to identify components (i.e., “symptom clusters”) from the 48 symptoms, 
since it was expected that the factors would be correlated (Henoch et al., 2009). To increase 
statistical robustness, have sufficient variation for EFAs and make clinically meaningful results, 
symptoms with prevalence less than 20% prevalence were excluded from the analysis. Cronbach’s 
α was examined to assess internal consistency. To establish the appropriateness of conducting an 
EFA, the Kaiser-Meyer-Olkin (KMO) statistic, and Bartlett test statistics were computed to 
measure sample adequacy. Eigenvalues, scree plots, and the amount of variance explained for each 
component from the EFA were used to determine the number of extracted components. The 
minimum factor loading of an individual symptom considered meaningful in this analysis was 0.40 
58 
(Browne, 2001). For items with cross-loadings, items were dropped if the difference between the 
primary loading and the secondary loading was less than 0.2. To define a symptom cluster, at least 
two symptoms must have loaded together, with the Cronbach α of the symptoms loading on the 
symptom cluster being greater than 0.60, and the correlation between the individual symptom and 
the symptom cluster greater than 0.25 (Ferketich, 1991). To compare the number and type of 
symptom clusters between two subgroups, we used the criteria developed by Kirkova and Walsh 
(Kirkova & Walsh, 2007). To conclude that both groups showed the same symptom cluster, “at 
least 75% of the symptoms within a cluster should be present, including the most prominent or 
important symptom” (Kirkova & Walsh, 2007, p.1012). For example, if only two possible 
symptoms were present in a symptom cluster, both groups should endorse both symptoms. If three 
possible symptoms were present in a symptom cluster, at least two important symptoms should be 
present in both groups. 
To identify symptom clusters for women with breast cancer prior to any adjuvant therapy, 
the recommended minimum sample size for EFA is at least 100 (MacCallum et al., 1999), with 
the criteria “100 = poor, 200 = fair, 300 = good, 500 = very good, ≥1000 = excellent” (Comrey & 
Lee, 2013), and the subjective-to-variable ratio is at least 5 (MacCallum et al., 1999). For 48 
symptoms, the recommended sample size based on the rule of thumb for is 48×5=240. Therefore, 
our sample (N=339) is large enough to conduct the EFA (339÷48=7.1, which is higher than 5).  
3.1.5  Results 
3.1.5.1 Sample characteristics 
The demographic and clinical characteristics of the sample are summarized in Table 5. All the 
patients were postmenopausal women with early-stage breast cancer who underwent surgery, with 
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a mean age of 61 (SD=6.2) years old. Most patients were Caucasian (96.5%), with a mean of 15 
years of education (SD=2.8), currently employed (70.4%), and married (67.8%). Except for age, 
stage of breast cancer and surgery type (p<.05), there were no significant differences in 
demographic and clinical characteristics between women in the ChemoAnast group and women in 
the AnastOnly group. Women received chemotherapy prior to AI therapy were significantly 
younger (p <.001), had more severe disease status (p <.001), and were more likely to have 
mastectomy (p =.016) than women in the AnastOnly group.  
Table 5 Sample Demographic and Clinical Characteristics (N=339) 
Characteristic Mean (SD) or n (%) Test statistic, p-value† 
Total 
(N=339) 
ChemoAnast 
(n=111) 
AnastOnly 
(n=228) 
Age (years) 61.2 (6.2) 59.3 (5.5) 62.1 (6.3) t=3.993, p=<.001 
Education (years) 14.9 (2.8) 15.0 (2.9) 14.8 (2.7) 
Employment status 
   Currently employed 238 (70.4%) 81 (73.0%) 157 (68.9%) 
   Unemployed 101 (29.6%) 30 (27.0%) 71 (31.1%) 
Married/partnered 
 Yes 231 (67.8%) 79 (71.2%) 152 (66.7%) 
    No 108 (32.2%) 32 (28.8%) 76 (33.3%) 
Race 
    White 329 (96.5%) 107 (96.4%) 222 (97.4%) 
   African American 10 (3.5%)  4 (3.6%) 6 (2.6%) 
Stage of breast cancer 
     I 227 (66.6%) 42 (37.8%) 185 (81.1%) U=6668.5, p=<.001 
     IIA 70 (20.5%) 35 (31.5) 35 (15.4%) 
     IIB 24 (7.0%) 17 (7.2) 7 (3.1%) 
     IIIA 18 (5.3%) 19 (5.7) 1 (0.4%) 
Surgery 
     Mastectomy 48 (14.1%) 23 (20.7%) 25 (11.0%) χ2=5.846, p=.016 
     Lumpectomy 278 (81.5%) 81(73%) 197 (86.4%) χ2=9.126, p=.003 
Radiation therapy 
     Yes 
      No        
 240 (70.8%) 
 19 (5.6%)   
85 (94.4%)  
5 (5.6%)      
155 (68.0%) 
14 (6.1%) 
 Missing data  80 (23.6%) 21 (18.9%) 59 (25.9%) 
Note: AI: aromatase inhibitor; AnastOnly: women prescribed anastrozole therapy only; ChemoAnast: women 
prescribed chemotherapy and anastrozole therapy; SD: standard deviation;  
†P value are from the student t test or Mann-Whitney U test for continuous variables and Pearson x2 tests for categorical 
variables, only P<.05 is listed in the table. 
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3.1.5.2 Symptom severity score between two groups 
The severity score for each symptom prior to AI therapy among women with breast cancer in 
ChemoAnast and AnastOnly groups are shown in Table 6. The most severe symptoms among 
women in the ChemoAnast group after chemotherapy but prior to AI therapy were: general aches 
and pains (M=34.5, SD=24.4), unhappy with the appearance of my body (M=33.3, SD=31.1), joint 
pains (M=33.0, SD=27.0), changes in sleep patterns (M=31.5, SD=25.5), and muscle stiffness 
(M=29.5, SD=26.8). The most severe symptoms among women in the AnastOnly group prior to 
AI therapy were: breast sensitivity (M=37.1, SD=30.2), unhappy with the appearance of my body 
(M=29.2, SD=28.7), general aches and pains (M=29.2, SD=23.6), joint pains (M=28.2, SD=26.5) 
and hot flashes (M=20.9, SD=27.0).  
Women in the ChemoAnast group experienced higher severity of symptoms than women 
in the AnastOnly group. Compared with women in the AnastOnly group prior to AI therapy, 
women in the ChemoAnast group experienced significantly lower severity of breast sensitivity (p 
=.01), but significantly higher severity of weight loss (p=0.047), genital itching (p=.029), changes 
in sleep pattern (p =.02), constipation (p =.02), avoidance of social affairs (p =.02), early 
awakening (p =.013), dry mouth (p =.01), perceived cognitive impairment (p =.01), muscle 
stiffness (p =.005), difficulty concentration (p =.003), fatigue (p =.001), forgetfulness (p <.001), 
easily distracted (p =<.001), numbness (p <.001), weight gain(p <.001), swelling of hands or feet 
(p <.001), blind spots (p <.001), diarrhea (p <.001), dizziness (p <.001), decreased appetite (p 
<.001), and nausea (p <.001) after chemotherapy but prior to AI therapy.  
Table 6 Symptom Mean Severity Scores Reported by Postmenopausal Women treated for Early 
Stage Breast Cancer 
Symptom 
Symptom Severity†   
Mean± SD with 95% CI Mean difference 
between groups 
(95%CI) Total ChemoAnast 
(T1) 
AnastOnly 
(T1) 
p-value‡
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Breast sensitivity/ 
tenderness 32.5 (30.1) 23.0 (27.6) 37.1 (30.2) 0.010 -14.1[-20.6,  -7.6]
Unhappy with the 
appearance of my 
body 30.9 (29.5) 33.3 (31.1) 29.7 (28.7) 0.374 3.6 [-3.3, 10.5] 
General aches and 
pains 30.9 (23.9) 34.5 (24.4) 29.2 (23.6) 0.060 
5.4 [-0.1, 10.9] 
Joint pains 29.7 (26.7) 33.0 (27.0) 28.2 (26.5) 0.089 4.8 [-1.3, 11.0] 
Muscle stiffness 24.0 (25.0) 29.5 (26.8) 21.3 (23.6) 0.005 8.2 [2.3, 14.1] 
Changes in sleep 
patterns 23.8 (26.5) 31.5 (25.5) 20.0 (26.2) 0.020 11.5 [5.6, 17.4] 
Fatigue 23.8 (23.5) 28.9 (23.8) 21.4 (23.1) 0.001 7.5 [2.1, 12.9] 
Early awakening 23.4 (26.7) 27.9 (27.1) 21.2 (26.3) 0.013 6.7 [0.6, 12.9] 
Hot flashes 21.7 (27.1) 23.2 (27.3) 20.9 (27.0) 0.432 2.3 [-3.9, 8.5] 
Tendency to take 
naps; stay in bed 21.2 (24.8) 25.7 (27.6) 19.1 (23.1) 0.046 6.6 [0.6, 12.6] 
Anxiety 19.0 (15.0) 19.0 (13.0) 19.0 (15.9) 0.420 0 [-3.3, 3.1] 
Pain 18.5 (21.5) 20.9 (23.8) 17.3 (20.2) 0.367 3.6 [-1.6, 8.8] 
Forgetfulness 18.4 (20.9) 24.8 (24.4) 15.2 (18.2) <.001 9.5 [4.4, 14.7] 
Vaginal dryness 18.2 (25.3) 20.9 (28.5) 16.9 (23.5) 0.349 4.1 [-2.1, 10.3] 
Night sweats 18.0 (25.7) 19.8 (27.6) 17.1 (24.8) 0.465 2.7 [-3.4, 8.8] 
Difficulty 
concentrating 17.8 (20.0) 22.7 (22.5) 15.5 (18.3) 0.003 
7.3 [2.4, 12.1] 
Easily distracted 16.0 (20.0) 21.4 (22.2) 13.3 (18.2) <0.001 8.1 [3.3, 12.9] 
Headaches 15.6 (19.7) 15.8 (20.8) 15.6 (19.0) 0.768 0.2 [-4.5, 4.7] 
Dry month 14.7 (24.6) 20.9 (28.3) 11.7 (22.0) 0.010 9.3 [3.2, 15.3] 
Numbness, tingling 13.9 (22.7) 23.2 (27.5) 9.4 (18.4) <0.001 13.8 [8.1, 19.5] 
Difficulty with 
bladder control at 
other times 13.7 (21.8) 15.3 (20.6) 12.9 (22.4) 0.091 
2.4 [-2.5, 7.2] 
Weight gain 12.9 (19.8) 18.0 (24.9) 10.5 (16.4) <0.001 7.4 [2.3, 12.6] 
Swelling of hands or 
feet 12.7 (21.4) 23.0 (26.6) 7.7 (16.3) <0.001 15.3 [9.9, 20.7] 
Constipation 12.7 (20.7) 15.5 (22.4) 11.3 (19.7) 0.020 4.2 [0.7, 9.1] 
Short temper 12.6 (18.0) 14.2 (19.0) 11.9 (17.5) 0.230 2.3 [-1.9, 6.5] 
Avoidance of social 
affairs 12.5 (21.2) 17.3 (23.1) 10.2 (19.8) 0.020 
7.1 [2.1, 12.2] 
Difficulty with 
bladder control when 
laughing or crying 12.4 (22.3) 13.7 (23.0) 11.7 (21.9) 0.469 2.0 [-3.2, 7.2] 
Perceived cognitive 
impairment 12.3 (9.3) 15.0 (10.4) 11.0 (8.5) 0.010 3.9 [1.7, 6.1] 
Blind spots 11.3 (20.8) 20.7 (26.7) 6.6 (15.3) <0.001 2.7 [8.7, 19.4] 
Pain with intercourse 10.8 (22.7) 10.4 (21.4) 11.1 (23.4) 0.917 -0.6 [-5.8, 4.5]
Excitability 9.7 (16.0) 11.3 (16.1) 8.9 (16.0) 0.106 2.4 [-1.3, 6.0] 
Ringing in ears 9.1 (20.1) 9.2 (19.6) 9.1 (20.4) 0.792 0.1 [-4.4, 4.7] 
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Diarrhea 8.4 (16.9) 11.7 (20.7) 6.8 (14.4) <0.001 4.9 [0.6, 9.2] 
Nausea 8.1 (16.9) 13.3 (21.3) 5.6 (13.6) <0.001 7.7 [3.3, 12.1] 
Decreased appetite 8.0 (16.9) 12.4 (21.6) 5.9 (13.6) <0.001 6.5 [2.1, 10.9] 
Genital itching 6.7 (15.1) 9.7 (19.4) 5.3 (12.2) 0.029 4.4 [0.4, 8.4] 
Weight loss 6.5 (14.8) 9.0 (17.8) 5.3 (12.9) 0.047 3.7 [0.4, 7.0] 
Dizziness 5.4 (14.1) 7.7 (15.4) 4.4 (13.3) <0.001 3.4 [0.2, 6.5] 
Depressive symptoms 5.3 (8.2) 5.8 (7.4) 5.1 (8.5) 0.115 0.7 [-1.0, 2.5] 
Difficulty breath 5.3 (14.4) 7.4 (15.7) 4.2 (13.7) 0.052 3.2 [-0.2, 6.5] 
Cold sweats 5.2 (16.2) 7.9 (19.1) 3.8 (14.4) 0.051 4.0 [-.4, 7.7] 
Tendency toward 
accidents 4.3 (11.2) 5.2 (12.7) 3.8 (10.4) 0.332 1.3 [-1.4, 4.1] 
Chest pain 3.6 (10.5) 3.9 (10.8) 3.4 (10.3) 0.710 0.5 [-2.0, 2.9] 
Vaginal discharge 2.9 (9.5) 3.2 (10.2) 2.9 (9.2) 0.999 0.3 [-2.0, 2.6] 
Cramps 2.0 (9.3) 2.7 (9.7) 1.6 (9.1) 0.163 1.1 [-1.1, 3.2] 
Vomiting 1.8 (8.4) 2.5 (10.1) 1.4 (7.5) 0.203 1.1 [-1.1, 3.2] 
Feelings of 
suffocation 1.5 (8.3) 1.6 (7.7) 1.4 (8.5) 0.519 
0.2 [-1.7, 2.0] 
Vaginal bleeding 0.3 (2.7) 0.2 (2.4) 0.3 (2.9) 0.740 -0.1 [-0.7, 0.5]
Note: AnastOnly: women prescribed anastrozole therapy only; ChemoAnast: women prescribed 
chemotherapy and anastrozole therapy; SD: standard deviation; CI: confidence interval; T0: after surgery 
and before the initiation of chemotherapy; T1: before the initiation of AI therapy for women in the 
AnastOnly group, after chemotherapy but prior to AI therapy for women in the ChemoAnast group 
 † Symptom severity was presented in a descending order; symptom severity was calculated based on the 
standardized scaling (0 to 100). 
‡p values are from Mann-Whitney U test 
3.1.5.3 Differences in symptom clusters between groups 
An eight-factor solution was identified from the EFA among women in the ChemoAnast group 
after chemotherapy and prior to the initiation of AI therap. Based on the symptoms in these 
clusters, we labelled them cognitive, musculoskeletal, psychological, vasomotor, weight, 
gastrointestinal (GI), urinary and sexual. Women in the AnastOnly group had seven similar 
symptom clusters prior to the initiation of AI therapy, except that the GI symptom cluster was not 
identified (see Table 7). Symptoms comprising some of the clusters differed between groups. For 
the cognitive symptom cluster, the total number of symptoms was 5 and the percent agreements 
were 100% for both groups. It consisted of symptoms including “easily distracted”, “perceived 
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cognitive impairment”, “difficulty concentrating”, and “forgetfulness”. For the musculoskeletal 
symptom cluster, the total number of symptoms ranged from 4 to 5 and the percent agreement was 
80% for ChemoAnast group and 100% for AnastOnly group. It consisted of “joint pain”, “general 
aches and pains”, and “general pain interference” for ChemoAnast group, with additional 
“swelling of hands” for AnastOnly group. For the “psychological” symptom cluster, the total 
number of symptoms ranged from 4 to 5 and the percent agreement was 80% for ChemoAnast 
group and 100% for AnastOnly group. “Fatigue”, “anxiety”, “depressive symptoms” and 
“avoidance of social affairs” clustered together as a “psychological” symptom cluster in the 
ChemoAnast group. In addition to these four symptoms, “changes in sleep pattern” clustered 
together with them in the AnastOnly group. The “urinary” symptom cluster consisted of “difficulty 
with bladder control when laughing or crying” and “difficulty with bladder control at other times” 
and the percent agreements were 100% for both groups.  The “vasomotor” symptom cluster 
consisted of “hot flashes” and “night sweats” and the percent agreements were 100% for both 
groups. The “sexual” symptom cluster consisted of “vaginal dryness” and “pain with intercourse” 
and the percent agreements were 100% for both groups. The “weight” symptom cluster consisted 
of “weight loss” and “decreased appetite” and the percent agreements were 100% for both groups. 
The “GI” symptom cluster consisted of “nausea” and “diarrhea”, and the percent agreement was 
100% for ChemoAnast group and 0% for AnastOnly group. 
Table 7 Symptom Clusters with Cluster Loadings† 
Symptom Cluster and 
Individual Symptom 
Cluster Loading 
AnastOnly(n=228) 
Cluster Loading  
ChemoAnast (n=111) 
Cognitive 
Difficulty concentrating .884 .889 
Easily distracted .816 .826 
Forgetfulness .763 .883 
Perceived cognitive (PAOFI) .530 .726 
Musculoskeletal 
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Joint Pain .926 .959 
General aches and pains .925 .814 
Muscle stiffness .721 .614 
Pain (BPI) .634 .693 
Swelling of hands or feet .456 - 
Psychological 
Depressive symptoms (BDI-II) .868 .733 
Anxiety (POMS) .602 .674 
Fatigue (POMS) .508 .438 
Avoidance of social affairs .590 .419 
Change in sleep pattern (BDI-II) .506 - 
Urinary 
Difficulty with bladder control 
when laughing or crying 
.899 .851 
Difficulty with bladder control at 
other times 
.820 .787 
Vasomotor 
Hot flashes .851 .833 
Night sweats .859 .806 
Sexual 
Pain with intercourse .731 .859 
Vaginal dryness .583 .769 
GI 
Diarrhea - .879 
Nausea - .579 
Weight 
Weight loss .731 .701 
Decreased appetite .729 .846 
Total variance explained 71.4% 74.3% 
Note: BCPT: AnastOnly: women prescribed anastrozole therapy only; ChemoAnast: women prescribed chemotherapy 
and anastrozole therapy; GI: gastrointestinal; BCPT: Breast Cancer Prevention Trial; BDI-II: Beck Depression 
Inventory-II; BPI: Brief Pain Inventory; PAOFI: Patient’s Assessment of Own Functioning; POMS: Profile of Mood 
States. 
†Of 33 symptoms with >20% prevalence, 16 did not co-occur with at least one other symptom, have a factor loading 
>.4, or symptom-total correlations > .25 (breast sensitivity, unhappy with the appearance of my body, early awakening, 
headaches, short temper, constipation, weight gain, dry mouth, excitability, numbness, vomiting, decreased appetite). 
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3.1.6  Discussion 
To our knowledge, this is the first study to examine and compare differences in the severity of 
symptoms and symptom clusters between women with breast cancer who did or did not receive 
chemotherapy prior to AI therapy using a comprehensive list of symptoms. To date only two 
studies have comprehensively examined patient-reported symptoms among women with breast 
cancer prior to AI therapy (Ganz et al., 2016; Kidwell et al., 2014). Kidwell et al. (2014) reported 
the rate of occurrence of depression, anxiety, sleep quality, fatigue, cognitive, musculoskeletal 
pain and vaginal dryness among postmenopausal women with breast cancer after chemotherapy 
and before AI therapy. Ganz and her colleagues (2016) measured the severity of endocrine therapy 
(ET)-related symptoms after chemotherapy and before ET to 12 months after the initiation of ET 
among pre-and postmenopausal women with breast cancer. This study found that cognitive 
problems, musculoskeletal pain, and hot flashes were the most severe symptoms among women 
with breast cancer prior to AI therapy. Taken together, the results of these studies suggest that a 
number of symptoms exist prior to AI therapy. Because the symptom dimension assessed by 
Kidwell et al. (2014) and the population in the study by Ganz el al. (2016) were different from the 
symptom dimension and population in our study, some caution should be taken when comparing 
the results of these studies. 
3.1.6.1 Differences in symptom severity score between two groups 
In general, women who received chemotherapy prior to AI therapy experienced more severe 
symptoms compared to women who did not receive it. In this study, the severity of 10 symptoms 
(i.e., forgetfulness, easily distracted, weight gain, numbness, decreased appetite, nausea, 
diarrhea, swelling of hands or feet, blind spots, dizziness) were significantly higher in the 
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ChemoAnast group than women in the AnastOnly group (p<.001). Most of these symptoms, 
such as decreased appetite, nausea, diarrhea, and difficulty breathing, have been reported among 
women with breast cancer during chemotherapy (Hsu et al., 2017; Carmen W Sullivan et al., 
2018). Our results add to the evidence that chemotherapy may exacerbate the severity of some 
symptoms experienced prior to AI therapy. It is possible that higher severity of these symptoms 
may be partially attributed to the influence of chemotherapy. However, in addition to receiving 
chemotherapy prior to AI therapy, research shows that women who are younger, have less 
education, have lower income, and have a higher comorbidity profile are more likely to 
experience higher severity of symptoms (S. H. Doong et al., 2015). In this study, women in the 
ChemoAnast group were younger, had greater stage of disease and were more likely to have 
received a mastectomy compared with the women in the AnastOnly group. Thus, more studies 
are needed to comprehensively identify predictors (i.e., treatment of chemotherapy, demographic 
and clinical characteristics, general health) of the pre-treatment symptom experience among 
women with breast cancer. 
It was also interesting to note that breast sensitivity was more severe in the AnastOnly 
group. A meta-analysis showed that breast pain after surgery is associated with younger age, 
radiation therapy, axillary lymph node dissection and it is not related to type of surgery or 
chemotherapy (Wang et al., 2016). In this study, women in the AnastOnly groups were younger 
than the ChemoAnast group, which could be one of the factors associated with higher severity of 
breast sensitivity. 
3.1.6.2 Differences in symptom clusters between two group 
The EFA results showed that the GI symptom cluster was only identified among women who 
received chemotherapy after surgery and prior to AI therapy. This symptom cluster has been 
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documented among women with breast cancer during and after chemotherapy, but with different 
specific symptoms within the symptom cluster. For example, Sullivan et al. (2018) identified that 
nausea and diarrhea clustered with lack of appetite, weight loss, change in the way food tastes, 
dry month, and abdominal cramps one week after chemotherapy. However, two weeks after 
chemotherapy, nausea clustered with feeling bloated, weight gain, and difficulty sleeping. 
Albusoul et al. (2017) assessed symptom clusters among women with breast cancer before, 
during and after chemotherapy and found that the GI symptom cluster was present before and 
during chemotherapy, but it no longer existed one month after chemotherapy. These results 
suggest that the GI symptom cluster persists several weeks after chemotherapy; however, it is not 
clear whether the GI symptom cluster is transient or how long it persists. Further research is 
warranted to fully understand the time course of GI symptoms after chemotherapy. 
3.1.6.3 Similarity in symptom severity score between two groups 
Our results showed that there were no differences in the severity of some symptoms between the 
two groups, including psychological (i.e., depressive symptoms, anxiety), musculoskeletal (i.e., 
joint pain, general aches and pains), sexual (i.e., pain with intercourse, vaginal dryness), vasomotor 
(i.e., hot flashes, night sweats) and urinary (i.e., difficulty with bladder control when laughing or 
crying) symptoms. This finding suggests that these symptoms are common among women with 
breast cancer prior to AI therapy regardless of whether they received chemotherapy or not. These 
symptoms may be related to natural menopausal changes, general health status, breast cancer 
and/or surgery prior to the initiation of AI therapy.  
Consistent with the results of our study, Marino et al. (2016) found that adjuvant 
chemotherapy does not influence the severity of vasomotor, and sexual symptoms among women 
with breast cancer, except for pain with intercourse. However, some studies suggest that 
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chemotherapy is associated with worsening vasomotor symptoms (Bernhard et al., 2007; Savard, 
Savard, Quesnel, & Ivers, 2009). These inconsistencies may be due to differences in samples 
across studies in terms of menopausal status and cancer treatments been received. More studies 
are needed to confirm the influence of chemotherapy on vasomotor and sexual symptoms among 
postmenopausal women with breast cancer prior to AI therapy.  
3.1.6.4 Similarity in symptom cluster between two groups 
Fatigue, anxiety, depressive symptoms and avoidance of social affairs clustered together in the 
ChemoAnast group, with additional symptom of changes in sleep pattern in the AnastOnly group. 
Findings from this study and other studies suggest that the psychological symptom cluster is 
present at the time of cancer diagnosis and can persist after surgery regardless of treatment received 
(Denieffe, S. Cowman, et al., 2014; Ho et al., 2015; Kidwell et al., 2014; Stacy D. Sanford et al., 
2014). Since it is the most common symptom cluster experienced by women with breast cancer, 
more studies are warranted to understand the underlying mechanisms and evaluate the trajectory 
of the psychological symptom cluster during AI therapy. 
For the cognitive symptom cluster, similar to this study, Bender et al. (2005) identified a 
perceived cognitive impairment symptom cluster consisting of problem with memory and loss of 
concentration. However, in other studies, some cognitive symptoms were found to cluster with 
other symptoms, such as outlook (Matthews et al., 2012), pain, shortness of breath and vomiting 
(Hsu et al., 2017). These differences can be explained by different cancer treatments patients 
received and different statistical methodologies used across studies. Since poor cognitive 
function pre-exists AI therapy in some women with breast cancer (Bender et al., 2015), it is 
important to assess and manage cognitive problems prior to AI therapy. Future research is 
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needed to develop and test the efficacy of useful interventions to manage cognitive problems 
specifically prior to AI therapy. 
For the musculoskeletal symptom cluster, general aches, joint pain, muscle pain were 
also reported among women with breast cancer in Marshall et al. (2016) and Roiland et al. 
(2011). Meanwhile, evidence suggests that general pain prior to AI therapy can predict higher 
severity of joint pain, fatigue and sleep disturbance among women with breast cancer during AI 
therapy (Shi et al., 2013). Management of musculoskeletal symptoms in advance of AI therapy 
may prevent worsening of symptoms with treatment. For example, physical activity, such as 
walking, has been shown to improve musculoskeletal symptoms among women with breast 
cancer receiving AI therapy (Nyrop et al., 2014).   
Vasomotor, urinary and sexual symptom clusters were present prior to AI therapy among 
women with breast cancer in both groups. No study has identified these symptom clusters prior 
to AI therapy, however, these symptom clusters have been identified at different assessment 
timepoints. Sullivan et al. (2018) identified the same vasomotor symptom cluster, consisting of 
hot flashes and night sweats, among women with breast cancer one week before chemotherapy. 
Vasomotor symptoms (i.e., hot flashes, night sweats), and sexual symptoms (i.e., vaginal 
dryness) also cluster together as a menopausal symptom cluster among women with breast 
cancer during chemotherapy and radiation therapy (Marshall et al., 2016).  
The limitations of this study are important to acknowledge. First, 97.0% women in this 
study were Caucasian. Thus, the generalizability of the study results was limited due to the racial 
homogeneity of the sample. Secondly, some symptoms, such as sleep disturbances, were measured 
in a very limited manner. In this study, only one item was used to assess sleep disturbances. A 
more comprehensive assessment of sleep disturbance may result in this symptom being featured 
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more prominently in the psychological symptom cluster. In addition, we only compared 
differences in symptom experience between treatment groups, we did not take all host factors into 
consideration. Other factors, such as demographic and clinical characteristics, personality, general 
health and comorbidities, menopausal status, duration of menopause, and genetic differences can 
influence the severity of symptoms prior to AI therapy as well. Future studies are needed to build 
a comprehensive model and consider the contribution of general physical health, personality, 
menopausal status, duration of menopause to the symptom experience reported by women with 
breast cancer prior to AI therapy. 
3.1.7  Conclusion 
It is of great significance to identify and compare the differences in the severity of symptoms and 
symptom clusters between postmenopausal women with early stage breast cancer who did and did 
not receive chemotherapy prior to AI therapy. Nurses should be aware that women who receive 
chemotherapy prior to AI therapy may experience specific severe chemotherapy related symptoms 
and symptom clusters. Psychological, musculoskeletal, sexual, urinary and vasomotor symptoms 
are common among women with breast cancer prior to AI therapy regardless of treatment with 
chemotherapy. Since symptoms may change over the course of AI therapy, additional research is 
warranted to evaluate the change of symptoms and symptom clusters over the course of AI therapy, 
and to evaluate the predictive relationship between symptom severity at baseline and symptom 
severity during AI therapy and adherence to AI therapy. 
Findings from our study provided a guide to assessment of symptoms in women with breast 
cancer prior to AI therapy. Nurses should be aware that women with breast cancer may experience 
cognitive, musculoskeletal, psychological, vasomotor, weight, sexual and urinary symptoms prior 
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to AI therapy. It is important for nurses to screen for these symptoms and manage them in advance. 
Knowing pre-treatment symptoms may be helpful in managing symptoms before treatment, since 
the burden of pre-treatment symptoms may be associated with worse symptoms during treatment 
and ultimately influence treatment adherence and women’s QOL. Furthermore, it is critical to 
educate patients about the symptom experience prior to AI therapy and teach them about symptom 
management strategies. Research shows that higher symptom management self-efficacy can 
reduce symptom distress among cancer patients (Liang et al., 2016). Early behavioral interventions 
(i.e., physical exercise, music therapy, acupuncture, mind-body therapies) can be provided to 
manage those symptoms prior to the initiation of AI therapy (Greenlee et al., 2017).   
3.2 STABILITY OF SYMPTOM CLUSTERS IN WOMEN WITH BREAST CANCER 
DURING THE FIRST 18 MONTHS OF ADJUVANT THERAPY 
3.2.1  Abstract 
Women with breast cancer treated with aromatase inhibitor (AI) therapy experience multiple 
concurrent symptoms or symptom clusters. These symptoms are the most commonly reported 
reason for nonadherence to cancer therapies. Therefore, understanding of the symptom 
experience and identifying symptom clusters before and during AI therapy are important for the 
development of interventions to improve clinical outcomes. The aim of this study was to identify 
symptom clusters experienced by women with breast cancer treated with AI therapy from pre-
adjuvant therapy up to 18 months of adjuvant therapy using a comprehensive symptom 
assessment. Forty-six symptoms were evaluated in postmenopausal women with breast cancer 
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(N=354) who received AI therapy or chemotherapy followed by AI therapy (ChemoAnast). 
Symptoms were assessed at four semi-annual time points with the Breast Cancer Prevention 
Trial Symptom Checklist, Patient’s Assessment of Own Functioning Inventory, Brief Pain 
Inventory, Beck Depression Inventory-II, and Profile of Mood States Tension/Anxiety and 
Fatigue/Inertia subscales. Exploratory factor analyses were conducted at each time point to 
identify symptom clusters. Four stable symptom clusters (i.e., musculoskeletal, vasomotor, 
urinary, sexual) and three relatively stable symptom clusters (i.e., psychological, neurocognitive, 
weight) were identified across the 18-month follow-up period. The gastrointestinal symptom 
cluster only appeared at after 6 months of adjuvant therapy (post-chemotherapy) in ChemoAnast 
group. This is the first study to examine symptom clusters over the 18 months of adjuvant 
therapy among postmenopausal women with early stage breast cancer. These findings may help 
guide symptom assessment and management in women with breast cancer during adjuvant 
therapy. 
3.2.2  Introduction 
In the United States, approximately 80% of women with breast cancer have hormone receptor 
positive disease (Lumachi et al., 2015). According to the ASCO guideline (Burstein et al., 2018), 
AI therapy for 5 years is the mainstay of endocrine therapy for postmenopausal women with 
hormone receptor positive breast cancer. 
The symptom experience after a cancer diagnosis may differ depending upon where 
patients are on the continuation of care. Symptoms may be related to menopausal status, pre-
existing symptoms related to comorbidities, cancer and cancer treatment received (Bodai & Tuso, 
2015; Bower et al., 2014). Once women begin adjuvant therapy, preexisting symptoms may be 
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exacerbated or change over time (Ganz et al., 2016). The most common symptoms associated with 
AI therapy are exacerbation of menopausal symptoms, musculoskeletal symptoms, and changes in 
cognitive function (Cella & Fallowfield, 2008; Rosenberg et al., 2015). Nonadherence to AI 
therapy is a challenging issue for both patients and clinicians. The overall AI therapy 
discontinuation rate is up to 50%, with 5%-25% being nonadherent in the first two years of 
treatment (Murphy, Bartholomew, Carpentier, Bluethmann, & Vernon, 2012). Symptoms related 
to endocrine therapy are the most common reasons for nonadherence among women with breast 
cancer (Aiello Bowles et al., 2012). With the increasing emphasis on survivorship needs of women 
with breast cancer, it is critical for healthcare providers to understand the burden of these 
symptoms, which influence adherence to treatment and compromise quality of life (QOL) (Chim 
et al., 2013; Ganz et al., 2016; Simon, Latreille, Matte, Desjardins, & Bergeron, 2014). 
Rather than study symptoms in isolation, research has focused on symptom clusters 
during chemotherapy and radiation therapy (Albusoul, Berger, Gay, Janson, & Lee, 2017; Hsu et 
al., 2017; Sullivan et al., 2018). However, few studies have assessed symptom clusters prior to 
adjuvant therapy or examined the long-term symptom burden of endocrine therapy, as most 
studies limit follow-up to less than one year post-therapy initiation (Cuzick, Sestak, Cella, & 
Fallowfield, 2008; Gallicchio, Calhoun, & Helzlsouer, 2017; Ganz et al., 2016). Little is known 
about how symptom clusters change over time from pre-adjuvant therapy and through AI 
therapy, or whether symptom clusters are a response to treatment or are preexisting. 
Accordingly, the goal of the current study was to conduct a comprehensive assessment of 
symptoms and identify symptom clusters that are present at four time points from pre-adjuvant 
therapy up to 18 months of adjuvant therapy among postmenopausal women with breast cancer. 
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We also compared symptom clusters between two cohorts of women who received 
chemotherapy plus AI therapy and women who received AI therapy only.  
3.2.3  Methods 
3.2.3.1 Study design 
This secondary analysis used symptom data from a prospective cohort, repeated measures study 
of cognitive function in postmenopausal women receiving anastrozole, an AI,  for early stage 
breast cancer (R01-CA107408) (Bender et al., 2015). All women completed surgery and 
received either (1) anastrozole therapy only (AnastOnly) or (2) chemotherapy followed by 
anastrozole therapy (ChemoAnast). All women with breast cancer completed the baseline 
assessment after primary surgery but prior to any adjuvant therapy. Symptom data were collected 
every 6 months from pre-adjuvant therapy (baseline) to 18 months post-baseline (see Table 8).  
Table 8 Time Points for Symptom Assessment 
Group Pre-chemo Chemotherapy Pre-AI 6 Months AI 12 Months AI 18 Months AI 
ChemoAnast X Yes X X X N/A 
AnastOnly N/A No X X X X 
Note: All women with breast cancer completed the baseline assessment after primary surgery but prior to any 
adjuvant therapy. For women in the ChemoAnast group, baseline is before chemotherapy. For women in the 
AnastOnly group, baseline is before anastrozole therapy. Women in the ChemoAnast group completed follow-up 
symptom assessments after chemotherapy but prior to anastrozole therapy, as well as 6 and 12 months after the 
initiation of anastrozole. Women in the AnastOnly group completed follow-up symptom assessments at 6, 12, and 
18 months after the initiation of anastrozole therapy.  
Note: AI: aromatase inhibitor; AnastOnly: women prescribed anastrozole therapy only; ChemoAnast: women 
prescribed chemotherapy and anastrozole therapy. 
3.2.3.2 Sample and setting 
Women with breast cancer were recruited from the Breast Cancer Program of the UPMC Hillman 
Cancer Center. This study was approved by the University of Pittsburgh Institutional Review 
Board, and all participants provided written informed consent. A total of 354 women with breast 
cancer were enrolled in the study. Women were eligible for this study if they were newly diagnosed 
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with early stage breast cancer, postmenopausal, less than 75 years old, scheduled to receive 
chemotherapy plus anastrozole or anastrozole alone, were able to speak and read English, and had 
a minimum of 8 years of education. Women were excluded if they had self-report of hospitalization 
for psychiatric illness, prior diagnosis of neurologic illness or cancer, or clinical evidence of distant 
metastases.  
3.2.3.3 Measurement 
Self-reported demographic and clinical characteristics from the medical record of participants were 
collected at baseline. Symptoms were measured by the Breast Cancer Prevention Trial (BCPT) 
symptom checklist, which includes cognitive, vasomotor, musculoskeletal pain, gastrointestinal, 
dyspareunia, bladder control, weight concerns, and gynecologic symptom subscales (Stanton et 
al., 2005). The measure assesses the severity of 42 bothersome symptoms whether the symptoms 
were bothersome on a 5-point Likert scale, from 0 (not at all) to 4 (extremely). 
Fatigue and anxiety were measured using the Profile of Mood States (POMS) by 
Fatigue/Inertia and Tension/Anxiety subscale, respectively (McNair et al., 1992). The POMS has 
been used to measure changes in mood in cancer patients (Meek et al., 2000). Symptoms were 
rated from 0=not at all to 4=extremely. Both POMS subscales have been widely used in cancer 
patients with adequate internal consistency reliability (Cronbach’s α >.87) (Baker, Denniston, 
Zabora, Polland, & Dudley, 2002). 
Pain was measured using 7 items from the Brief Pain Inventory-Short Form (BPI-short) 
(Cleeland & Ryan, 1994). Patients were asked to indicate their pain intensity on a scale from 0 (no 
pain) to 10 (pain as bad as you can imagine). Investigators have used BPI to assess pain among 
patients with cancer with well-established reliability and validity (Caraceni, 2001; Tittle et al., 
2003). 
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Depressive symptom severity was measured using total score of items 1-14 from the Beck 
Depression Inventory-II (BDI-II) (Beck et al., 1996). Symptom severity scores can range from 0 
(no symptom) to 3 (severe symptom). High reliability and validity have been demonstrated for the 
BDI-II (Wang & Gorenstein, 2013), with strong internal consistency (Cronbach’s α=0.93) among 
cancer patients (Hopko et al., 2007). Changes in sleep pattern was assessed using the score in the 
sleep item on the BDI-II.  
Perceived cognitive impairment was measured by the Patient’s Assessment of Own 
Functioning (PAOFI) (Chelune et al., 1986). Items were rated from 0 (almost never) to 5 (almost 
always). The PAOFI has been used in studies among women with breast cancer, with adequate 
internal consistency and construct validity (Bell et al., 2013).  
3.2.3.4 Data analysis 
Descriptive statistics were used to summarize the demographic and clinical characteristics for the 
total sample and by two groups of women based on chemotherapy status (chemotherapy plus 
anastrozole or anastrozole alone). Treatment groups were compared with Mann-Whitney U test 
for continuous variables, and chi-square test of independence for categorical variables. All 
analyses were completed using IBM® SPSS® Statistics Version 25 (IBM Corp., Armonk, NY).  
Exploratory factor analysis (EFA) was conducted using principal axis factoring (PAF) as 
the extraction method followed by promax rotation method to identify symptom clusters from the 
48 symptoms, since PAF explain the correlations among symptoms and promax rotation assumes 
that the factors are correlated. To increase clinical significance, symptoms with a prevalence of 
less than 20% were excluded from the analysis. The minimum factor loading of an item considered 
meaningful in this analysis was 0.40 (Browne, 2001). To be defined as a symptom cluster, at least 
two symptoms had to load together, with a Cronbach α greater than 0.60 and  symptom-total 
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correlations greater than 0.25 (Ferketich, 1991). Separate EFAs were performed at the four time 
points to investigate the stability of the composition of the symptom clusters over time. To explore 
differences of symptom cluster between two treatment groups, EFAs were conducted separately 
in ChemoAnast and AnastOnly groups at each of the four time points. 
3.2.4  Results 
3.2.4.1 Demographic and clinical characteristics of the sample 
The demographic and clinical characteristics for the total sample and by treatment group are 
summarized in Table 9. A total of 354 postmenopausal women with early stage breast cancer were 
on average 61 years (SD=6.2) of age and 15 years (SD=2.8) of education. Most participants were 
Caucasian (96.3%), currently employed (70.7%), and married (67.3%). The majority of patients 
had stage I breast cancer (65.6%) and 81.7% of the sample received lumpectomy. Even though 
women in the AnastOnly group (M=62.1) were statistically significantly (P<0.001) older than 
women in the ChemoAnast group (M=59.6), the differences in age were likely not clinically 
meaningful. In terms of clinical characteristics, women in the AnastOnly group were more likely 
to have had a lumpectomy (P=0.002), and have a lower disease stage (P<0.001) than women in 
the ChemoAnast group.  
Table 9 Demographic and Clinical Characteristics 
Characteristic Mean (SD) or n (%) Test Statistic, p value† 
Total 
(n=354) 
ChemoAnast 
(n=127) 
AnastOnly  
(n=227) 
Age (years) 61.2 (6.2) 59.6 (5.4) 62.1 (6.3) U=11373.5, p<0.001 
Education (years) 14.9 (2.8) 14.8 (2.9) 14.8 (2.7) 
Employment status 
 Currently employed 251 (70.7%) 94 (74.0%) 157 (68.9%) 
  Unemployed/retired/student 104 (29.3%) 33 (26.0%) 71 (31.1%) 
Married/partnered 
     Yes 239 (67.3%) 87 (68.5%) 152 (66.7%) 
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    No 116 (32.7%) 40 (31.5%) 76 (33.3%) 
Race 
  White 342 (96.3%) 120 (94.5%) 222 (97.4%) 
  African American 13 (3.7%)  7 (4.5%) 6 (2.6%) 
Stage of breast cancer 
  I 233 (65.6%) 48 (37.8%) 185 (81.1%) U=7648.5, p<0.001 
 IIA 76 (21.4%) 41 (32.3) 35 (15.4%) 
 IIB 27 (7.6%) 20 (15.7) 7 (3.1%) 
      IIIA 19 (5.4%) 18 (14.2) 1 (0.4%) 
Surgery 
 Mastectomy 51 (14.4%) 26 (20.5%) 25 (11.0%) χ2=5.993, p=0.014 
      Lumpectomy 290 (81.7%) 93 (73.2%) 197 (86.4%) χ2=9.466, p=0.002 
Note: U= Mann–Whitney U; AnastOnly: women prescribed anastrozole therapy only; ChemoAnast: women 
prescribed chemotherapy and anastrozole therapy. 
†P value are from the student t test or Mann-Whitney U test for continuous variables and Pearson chi-square tests of 
independence for categorical variables, only those characteristics that demonstrated statistically significant differences 
(p<.05) between the two treatment groups are reported in the table. 
3.2.4.2 Changes in symptom clusters over time 
Multiple symptom clusters were identified at four time points (see Table 10). Based on the 
characteristics of the symptoms loading on a symptom cluster, eight distinct symptom clusters 
were revealed and were labeled as: cognitive, psychological, musculoskeletal, vasomotor, 
urinary, sexual, weight, and gastrointestinal (GI). All the symptom clusters were present at 
baseline and lingered over time during AI therapy, except for the GI symptom cluster. 
The musculoskeletal, vasomotor, urinary, sexual symptom cluster were most stable over 
time with the same symptoms with the symptom clusters from pre-adjuvant therapy to 18 months. 
Symptoms in the musculoskeletal symptom cluster included general aches, joint pain, muscle 
stiffness, and general pain intensity. The vasomotor symptom cluster consisted of hot flashes and 
night sweats. The urinary symptom cluster comprised difficulty with bladder control when 
laughing or crying and difficulty with bladder control at other times. The sexual symptom cluster 
consisted of vaginal dryness and pain with intercourse. 
The neurocognitive, psychological, and weight symptom clusters were relatively stable 
over time with some changes in symptoms within the symptom clusters at some time points. 
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Across the first three time points, difficulty concentrating, being easily distracted, forgetfulness, 
and perceived cognitive disturbance were stable within the cognitive symptom cluster, with the 
addition of dry mouth at 6 months, and symptom excitability, short temper, and tendency toward 
accidents at 12 months. Fatigue and depressive symptoms were stable within the psychological 
symptom cluster from baseline to 12 months. However, the cognitive and the psychological 
symptom cluster merged into a psychoneurocognitive symptom cluster at 18 months, which 
consisted of fatigue, depressive symptoms, anxiety, difficulty concentrating, being easily 
distracted, forgetfulness, excitability, and short temper. The weight symptom cluster, consisting of 
weight gain and unhappiness with appearance, was stable from 6 months to 18 months. However, 
these two symptoms were not present at baseline. Instead, weight loss and decreased appetite 
clustered together at baseline.  
The GI symptom cluster was not stable over time. It was only observed at 6 months and 
consisted of nausea and diarrhea. At 12 and 18 months, nausea was not included in the EFA 
because of its low prevalence (<20%). 
Table 10 Symptom Clusters with Factor Loadings at Four Time Points 
Baseline 6 Months 12 Months 18 months 
Psychological 
depressive symptoms 
(0.681), 
anxiety (0.640),  
changes in sleep patterns 
(0.569), 
avoid of social affairs 
(0.566), 
fatigue (0.505), 
Psychological 
anxiety (0.843),  
depressive symptoms 
(0.811),  
avoid of social affairs 
(0.548),  
fatigue (0.475),  
short temper (0.402) 
Psychological 
fatigue (0.726),  
changes in sleep patterns 
(0.575), 
depressive symptoms 
(0.439) 
Psychoneurocognitive 
excitability (0.884),  
forgetfulness (0.819),  
anxiety (0.779),  
difficulty concentrating 
(0.729),  
easily distracted (0.723), 
depressive symptoms 
(0.707),  
fatigue (0.444),  
short temper (0.443) 
Neurocognitive 
difficulty concentrating 
(0.899),  
easily distracted (0.866), 
forgetfulness (0.747), 
perceived cognitive 
disturbance (0.593) 
Neurocognitive 
difficulty 
concentrating (0.937), 
forgetfulness (0.872), 
easily distracted 
(0.854),  
perceived cognitive 
disturbance (0.692), 
dry mouth (0.417) 
Neurocognitive 
easily distracted (0.929), 
difficulty concentrating 
(0.911),  
excitability (0.782),  
perceived cognitive 
disturbance (0.733), 
forgetfulness (0.721), 
short temper (0.578), 
tendency toward accidents 
(0.452), 
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anxiety (0.400) 
Musculoskeletal 
joint pain (0.915),  
general aches (0.814),  
muscle stiffness (0.719), 
general pain (0.535) 
Musculoskeletal 
general aches (0.842), 
joint pain (0.920),  
muscle stiffness 
(0.703),  
general pain (0.456) 
Musculoskeletal 
joint pain (0.964),  
general aches (0.802),  
muscle stiffness (0.623), 
general pain (0.500) 
Musculoskeletal 
joint pain (0.955), 
general pain (0.817), muscle 
stiffness (0.767),  
general aches (0.603) 
Vasomotor 
night sweats (0.880), 
hot flashes (0.857) 
Vasomotor 
night sweats (0.874), 
hot flashes (0.865) 
Vasomotor 
hot flashes (0.891), 
night sweats (0.697) 
Vasomotor 
night sweats (0.854), 
hot flashes (0.806) 
Bladder 
difficulty with bladder 
control when laughing or 
crying (0.908),  
difficulty with bladder 
control at other times 
(0.818) 
Bladder 
difficulty with bladder 
control at other times 
(0.858), 
difficulty with bladder 
control when laughing 
or crying (0.750)  
Bladder 
difficulty with bladder 
control at other times 
(0.834)，difficulty with 
bladder control when 
laughing or crying (0.709) 
Bladder 
difficulty with bladder 
control when laughing or 
crying (0.773),  
difficulty with bladder 
control at other times 
(0.605) 
Sexual 
vaginal dryness (0.833), 
pain with intercourse 
(0.554) 
Sexual 
vaginal dryness 
(0.843),  
pain with intercourse 
(0.712) 
Sexual 
vaginal dryness (0.872), 
pain with intercourse 
(0.809) 
Sexual 
vaginal dryness (0.846), 
pain with intercourse 
(0.771) 
Weight 
decreased appetite 
(0.803), 
weight loss (0.600) 
Weight 
unhappy with the 
appearance of my 
body (0.821), 
weight gain (0.575) 
Weight 
weight gain (0.840),  
unhappy with the 
appearance of my body 
(0.602) 
Weight 
weight gain (0.661),  
unhappy with the 
appearance of my body 
(0.606) 
N/A GI 
diarrhea (0.938), 
nausea (0.694) 
N/A N/A 
3.2.4.3 Differences in symptom clusters between the two groups 
Table 11 and 12 showed the symptom clusters among women in ChemoAnast, and AnastOnly 
groups, respectively. At baseline and 18 months, fatigue and changes in sleep patterns clustered 
together with other psychological symptoms in AnastOnly group. These two symptoms stood out 
as a unique symptom cluster in ChemoAnast group. The GI symptom cluster was identified at 6 
months in ChemoAnast group only. At 12 months, fatigue and depressive symptoms clustered with 
musculoskeletal symptoms in AnastOnly group.  
Table 11 Table Symptom Clusters at Four Time Points for ChemoAnast Group 
Baseline 6 Months 12 Months 18 months 
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Psychological 
unhappy with the  
appearance of my body 
(0.743), 
depressive symptoms 
(0.635), 
short temper (0.547), 
avoid of social affairs 
(0.497), 
anxiety (0.444) 
Psychological 
depressive symptoms 
(0.737),  
anxiety (0.713),  
avoid of social affairs 
(0.477), 
fatigue (0.473) 
Psychological 
fatigue (0.748),  
avoid of social affairs 
(0.663), 
changes in sleep pattern 
(0.521) 
Psychoneurological 
easily distracted 
(0.900),  
excitability (0.832), 
forgetfulness (0.823),  
difficulty concentrating 
(0.787),  
anxiety (0.730),  
depressive symptoms 
(0.488),  
short temper (0.428) Neurocognitive 
difficulty concentrating 
(0.887),  
forgetfulness (0.875), 
easily distracted (0.858), 
perceived cognitive 
disturbance (0.613) 
Neurocognitive 
forgetfulness (0.968), 
difficulty concentrating 
(0.803),  
easily distracted (0.745), 
perceived cognitive 
disturbance (0.735), 
dry mouth (0.636), 
excitability (0.517) 
Neurocognitive 
difficulty concentrating 
(0.925),  
easily distracted (0.991),  
forgetfulness (0.762), 
perceived cognitive 
disturbance (0.704), 
anxiety (0.604), 
excitability (0.549),  
tendency toward accidents 
(0.465), 
Musculoskeletal 
joint pain (0.959), 
general aches (0.834),  
muscle stiffness (0.517) 
Musculoskeletal 
joint pain (0.977), general 
aches (0.841),  
muscle stiffness (0.663),  
general pain (0.645) 
Musculoskeletal 
general aches (0.930),  
joint pain (0.961),  
muscle stiffness (0.681), 
general pain (0.645), 
unhappy with the 
appearance of my body 
(0.457), 
Musculoskeletal 
joint pain (0.972),  
general aches (0.879), 
muscle stiffness 
(0.758),  
general pain (0.704), 
numbness (0.576), 
swelling of hands or 
feet (0.520) 
Vasomotor 
night sweats (0.933), 
hot flashes (0.904) 
Vasomotor 
hot flashes (0.809),  
night sweats (0.804) 
Vasomotor 
hot flashes (0.823),  
night sweats (0.753) 
Vasomotor 
night sweats (0.916), 
hot flashes (0.751) 
Bladder 
difficulty with bladder 
control when laughing or 
crying (0.962) 
difficulty with bladder 
control at other times 
(0.821) 
Bladder 
N/A 
Bladder 
difficulty with bladder 
control at other times 
(0.901), 
difficulty with bladder 
control when laughing or 
crying (0.725) 
Bladder 
difficulty with bladder 
control when laughing 
or crying (0.716),  
difficulty with bladder 
control at other times 
(0.498) 
N/A Sexual 
pain with intercourse 
(0.828), 
vaginal dryness (0.804) 
Sexual 
vaginal dryness (0.941), 
pain with intercourse 
(0.842) 
Sexual 
pain with intercourse 
(0.991), 
vaginal dryness (0.677) 
Weight 
weight gain (0.628), 
swelling of hands or feet 
(0.551) 
Weight 
weight gain (0.680)  
decreased appetite  
(-0.639), 
weight loss (-0.550), 
unhappy with the 
appearance of my body 
(0.445) 
Weight 
dry mouth (0.606), 
weight gain (0.593) 
Weight 
weight gain (0.732),  
unhappy with the 
appearance of my body 
(0.707) 
Sickness 
changes in sleep patterns 
(0.721), 
N/A N/A Sickness 
fatigue (0.876), 
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fatigue (0.557) changes in sleep 
patterns (0.572) 
N/A GI 
Nausea (0.663), 
Diarrhea (0.860), 
blind spots (0.456) 
N/A N/A 
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Table 12 Symptom Clusters at Four Time Points for AnastOnly Group 
Baseline 6 Months 12 Months 18 months 
Psychological 
depressive symptom 
(0.760), 
avoid of social affairs 
(0.685), 
anxiety (0.626),  
fatigue (0.498) 
changes in sleep 
patterns (0.488) 
Psychological 
depressive symptom 
(0.765),  
avoid of social affairs 
(0.671), 
anxiety (0.581),  
general pain (0.541),  
decreases appetite 
(0.515), 
fatigue (0.505),  
headaches (0.453) 
N/A Psychoneurocognitive 
excitability (0.945),  
perceived cognitive 
disturbance (0.877), 
depressive symptom 
(0.762), forgetfulness 
(0.750),  
anxiety (0.738), difficulty 
concentrating (0.559),  
easily distracted (0.473) 
Neurocognitive 
difficulty 
concentrating (0.854), 
easily distracted 
(0.814),  
forgetfulness (0.770), 
perceived cognitive 
disturbance (0.607), 
short temper (0.415) 
Neurocognitive 
difficulty concentrating 
(0.961),  
forgetfulness (0.849), 
easily distracted (0.844), 
perceived cognitive 
disturbance (0.696), 
blind spots (0.487) 
Neurocognitive 
difficult concentrating 
(0.989),  
easily distracted (0.913), 
excitability (0.800),  
perceived cognitive 
disturbance (0.761), 
forgetfulness (0.708), 
anxiety (0.604), 
avoidance of social affairs 
(0.563), 
tendency toward accidents 
(0.465) 
Musculoskeletal 
joint pain (0.906),  
general aches (0.837), 
muscle stiffness 
(0.749),  
swelling of hands or 
feet (0.551), 
numbness (0.448) 
Musculoskeletal 
general aches (0.901), 
joint pain (0.814),  
muscle stiffness (0.715) 
Musculoskeletal-
depressive symptoms 
joint pain (0.949),  
general aches (0.862), 
muscle stiffness (0.506), 
fatigue (0.485),  
general pain (0.416), 
depressive symptoms 
(0.408) 
Musculoskeletal 
general pain (0.891), 
joint pain (0.832),  
muscle stiffness (0.693) 
Vasomotor 
night sweats (0.854), 
hot flashes (0.835) 
Vasomotor 
hot flashes (0.925),  
night sweats (0.846) 
Vasomotor 
night sweats (0.917), 
hot flashes (0.812) 
Vasomotor 
night sweats (0.944), 
hot flashes (0.807)  
Bladder 
difficulty with bladder 
control when laughing 
or crying (0.872),  
difficulty with bladder 
control at other times 
(0.743) 
Bladder 
difficulty with bladder 
control when laughing or 
crying (0.852), 
difficulty with bladder 
control at other times 
(0.844) 
Bladder 
difficulty with bladder 
control at other times 
(0.676), 
difficulty with bladder 
control when laughing or 
crying (0.809) 
Bladder 
difficulty with bladder 
control when laughing or 
crying (0.969),  
difficulty with bladder 
control at other times 
(0.774) 
Sexual 
vaginal dryness,  
pain with intercourse 
Sexual 
vaginal dryness (0.767), 
pain with intercourse 
(0.742) 
Sexual 
vaginal dryness (0.853), 
pain with intercourse 
(0.770) 
Sexual 
pain with intercourse 
(0.832), 
vaginal dryness (0.726) 
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Weight 
weight gain,  
decreased appetite 
Weight 
unhappy with the 
appearance of my body 
(0.757), 
weight gain (0.705)  
Weight 
weight gain (0.759),  
unhappy with the 
appearance of my body 
(0.589), 
dry mouth (0.469) 
Weight 
weight gain (0.737),  
unhappy with the 
appearance of my body 
(0.708) 
3.2.5  Discussion 
This is the first study to evaluate and descriptively compare changes in the composition of 
symptom clusters among two cohorts of women with breast cancer treated with AI therapy from 
pre-adjuvant therapy to 18-months adjuvant therapy. We will discuss each symptom cluster 
separately based on the specific symptoms within the cluster and their stability.  
3.2.5.1 Psychological and neurocognitive symptom clusters 
In this study, the main symptoms in the psychological symptoms were fatigue, anxiety and 
depressive symptoms. In other studies, depressive symptoms, anxiety and fatigue also clustered 
with sleep disturbance, cognitive symptoms, and pain (Kim, Barsevick, Tulman, & McDermott, 
2008; Langford et al., 2016; Starkweather et al., 2017). The main symptoms in the neurocognitive 
symptom cluster are difficulty concentrating, being easily distracted, forgetfulness, and perceived 
cognitive disturbance. Similar to our finding, Roiland et al. (2011) identified a symptom cluster 
consisting of balance problems, dizziness, memory problems, and trouble concentrating among 
breast cancer survivors. In other studies, cognitive symptoms clustered with outlook (worry about 
future) (Matthews et al., 2012), pain, shortness of breath and vomiting (Hsu et al., 2017). 
It was worth noting that that psychological symptoms clustered with neurocognitive 
symptoms into a psychoneurocognitive symptom cluster at 18 months. Sullivan et al.(2018) also 
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found that some cognitive symptoms (i.e., difficulty concentrating) clustered with psychological 
symptoms among women with breast cancer during chemotherapy. These findings suggest that 
common biological mechanisms may exist between psychological and cognitive symptoms since 
they are usually highly correlated. Meanwhile, fatigue and changes in sleep patterns did not cluster 
with psychological symptoms at baseline and 18 months for women in the ChemoAnast group. It 
suggests that behavioral symptoms (i.e., fatigue, sleep problems) may have different biological 
mechanisms with psychological and neurocognitive symptoms even though they are usually highly 
correlated. Prior studies have related higher overall burden of fatigue, sleep problems, depressive 
symptom, anxiety and pain to increases in levels of systemic inflammation, resulting in the 
experience of sickness (Wang et al., 2010). Future studies are needed to examine whether 
psychological, behavioral and neurocognitive symptoms have common or disparate biological 
mechanisms. 
Results from the current study suggest that the psychological and neurocognitive symptom 
clusters persist for a long time. Healthcare providers should assess patients’ psychological 
symptoms both during cancer diagnosis and during long-term cancer treatment and should 
integrate mental health with cancer care when needed.   
3.2.5.2 Musculoskeletal, vasomotor, urinary and sexual symptom clusters 
In this study, the musculoskeletal, vasomotor, urinary and sexual symptom cluster appeared prior 
to adjuvant therapy and they were stable over the 18 months of adjuvant therapy.  
Consistent with the current results, Sullivan et al. (2018) identified the same hormonal 
symptom cluster, consisting of hot flashes and night sweats among both pre- and post-menopausal 
women with breast cancer before and during chemotherapy. Night sweats and hot flashes can also 
cluster with some psychoneurological symptoms (i.e., feeling irritable, difficulty concentrating, 
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mood swings) before and after chemotherapy (Phligbua et al., 2013). It was interesting to note that 
fatigue and depressive symptoms clustered together with musculoskeletal symptoms at 12 months 
post-AI therapy in AnastOnly group. Consistent with this study, previous studies found that 
general aches, joint pain, and muscle pain clustered together with other symptoms (i.e., fatigue, 
weakness, headaches) (Marshall et al., 2016; Roiland & Heidrich, 2011). These studies suggest 
that fatigue and depressive symptoms are highly associated with musculoskeletal symptoms 
among women with breast cancer. Therefore, it is important to manage fatigue, depressive 
symptoms and musculoskeletal symptoms together. 
Only two studies have reported urinary and sexual symptom clusters among women with 
breast cancer. Roiland et al. (2011) found that incontinence, increased urination, decreased sex 
drive, and irritated eyes clustered together among breast cancer survivors. In Yates et al. (2015), 
urinary problems clustered with sexual problems among younger (<60 years) cancer patients, 
whereas urinary problems clustered with problems with sexual interest, diarrhea, and irritability 
among older (≥60 years) cancer patients. Urinary and sexual symptoms merged into one symptom 
cluster among those studies; however, they were identified as unique symptom clusters in our 
study. Compared to those two studies, our study has a more homogenous sample in terms of cancer 
type (breast cancer versus breast, prostate, lung and other cancer) and menopausal status 
(postmenopausal versus pre- and postmenopausal).  
Since these symptom clusters may be attributed to the impact of reduced estrogen with AI 
therapy or menopause status (Lønning, 1996), more studies are warranted to explore trajectories 
of these symptom clusters while considering age and menopause status as influential factors. 
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3.2.5.3 GI symptom cluster 
In this study, the GI symptom cluster was only identified at 6 months among women in the 
ChemoAnast group. The appearance of the GI symptom cluster was not related to AI therapy. 
Although we did not record the exact date of completion of chemotherapy in this group, the results 
raise the possibility that symptoms of nausea and vomiting resulting from chemotherapy lingered 
weeks after chemotherapy and present prior to AI therapy. More studies are needed to confirm the 
duration of the GI symptom cluster after chemotherapy.  
The GI symptom cluster has been reported in other studies as well. However, symptoms 
within the GI symptom cluster varied across studies. Kim et al. (2008) identified that nausea and 
vomiting clustered with decreased appetite among women with breast cancer 48 hours after 
chemotherapy. In Sullivan et al. (2018) study, nausea sometimes clustered with weight loss, weight 
gain, lack of appetite, and diarrhea as a nutritional symptom cluster and sometimes clustered with 
feeling bloated and abdominal cramps as a GI symptom cluster. Hsu et al. (2017) found that nausea 
clustered with emotional symptoms and peaked at 3 to 5 days during chemotherapy and gradually 
decreased till the end of 21-day chemotherapy cycle. Future research is needed to evaluate the 
relationship between GI, nutritional and emotional symptoms among women with breast cancer.  
3.2.5.4 Weight symptom cluster 
The symptoms within the weight symptom cluster changed from baseline to 6 months and then 
were stable over time after AI therapy was initiated. At baseline, weight loss and decreased appetite 
clustered together. This result was consistent with Sullivan et al. (2018) study which showed that 
weight gain clustered with weight loss and decreased appetite one week prior to chemotherapy, 
then disappeared during and after chemotherapy. In the current study, weight gain and unhappy 
with the appearance clustered together from 6 months to 18 months. Few studies have identified 
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weight gain and unhappiness with appearance, as these two symptoms are not included in most 
symptom scales, such as the Memorial Symptom Assessment Scale (Portenoy et al., 1994). This 
study indicates the need to include weight gain and satisfaction with appearance in future symptom 
research. More studies are needed to confirm the weight symptom cluster among women with 
breast cancer during AI therapy.  
3.2.5.5 Limitations 
Some limitations are important to consider in this study. First, 96% of our sample was Caucasian. 
The racial homogeneity of the sample may influence the study result. Secondly, the recommended 
sample size for EFA is at least 300, with the criteria “100 = poor, 200 = fair, 300 = good” 
(MacCallum et al., 1999). Our sample (N=354) is sufficient to conduct exploratory factor analysis 
at baseline. However, our sample size is not sufficient to conduct exploratory factor analysis 
separately for women in the ChemoAnast (n=127) group and women in the AnastOnly (n=227) 
group. The comparisons that were accomplished over time and between the two treatment cohorts 
were purely descriptive and exploratory. Future efforts are needed to expand the study in larger, 
more racially diverse sample. Lastly, differences in the dimensions of symptoms (i.e., occurrence, 
severity, distress) may influence clustering of symptoms. We only identified symptom clusters 
using a symptom severity score. Future research is needed to examine different dimensions of 
symptoms when identifying symptom clusters. 
3.2.6  Conclusion 
We identified four stable symptom clusters with the same symptoms within the symptom clusters 
from pre-adjuvant therapy to 18 months post adjuvant therapy (i.e., musculoskeletal, vasomotor, 
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urinary, sexual), and three relatively stable symptom clusters with some changes in symptoms 
within the symptom clusters at some time points (i.e., psychological, neurocognitive, weight) 
among postmenopausal women with early stage breast cancer. These symptom clusters exist prior 
to any adjuvant treatment and persist for the first 18 months of adjuvant therapy. The GI symptom 
cluster only appeared at 6-month time point of adjuvant therapy in ChemoAnast group (i.e., post 
chemotherapy). It is important for health care providers to educate women with breast cancer that 
many symptom clusters may already exist before adjuvant therapy, the presence of these symptom 
clusters may relate to menopause, general health status, cancer pathophysiology, or other 
demographic or clinical characteristics, but symptoms are not all sue to the effect of adjuvant 
therapy. Adjuvant therapy may exacerbate these preexisting symptoms. Further studies are needed 
to confirm these findings by evaluating trajectories of the stable symptom clusters and identifying 
predictors related to these symptom clusters.  
The current findings inform future research by introducing symptoms for assessments and 
through suggesting shared biological mechanisms. Since AI therapy is usually prescribed for 5 to 
10 years, it is critical for health care providers to know the symptom clusters experienced by 
women receiving this treatment and manage them properly over time in order to improve 
adherence. This is particularly important given low levels of adherence to this prolonged treatment, 
with some indication that women stop taking the medication due to ongoing symptoms. Future 
studies are needed to explore the biological mechanisms underlying each symptom cluster and to 
identify both phenotypic and genotypic factors that influence the inter-individual differences of 
the symptom cluster experience.  
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3.3 GENES INVOLVED IN THE HPA AXIS AND THE SYMPTOM CLUSTER OF 
FATIGUE, DEPRESSIVE SYMPTOM AND ANXIETY IN WOMEN WITH 
BREAST CANCER DURING 18 MONTHS OF ADJUVANT THERAPY 
3.3.1  Abstract 
Fatigue, depressive symptom and anxiety frequently coexist throughout cancer diagnosis and 
treatment trajectory among women with breast cancer. Research shows that dysregulation of the 
hypothalamic-pituitary-adrenal (HPA) axis may contribute to these contemporaneous symptoms. 
Individual differences in genetics may also contribute to the risk for this psychological symptom 
cluster via association with HPA axis function. The aims of this study were to (1) identify 
subgroups of postmenopausal women with distinct experiences with the psychological symptom 
cluster from pre-adjuvant therapy through the first 18 months after starting adjuvant therapy and 
(2) explore associations between demographic and clinical characteristics and variation in genetic
polymorphisms related to HPA axis function and the predicted symptom trajectory subgroup 
membership. Genetic data were collected in a subgroup at pre-adjuvant therapy (N=184), and 
symptom data were collected semi-annually at four time points from baseline to 18-month follow-
up (N=292). Group-based multi-trajectory modeling was used to classify women with breast 
cancer into subgroups with similar psychological symptom cluster trajectories over the course of 
their adjuvant therapy. Binary logistic regression analysis was used to explore the associations 
between each genotypic and phenotypic predictor and predicted trajectory subgroup membership. 
Two distinct symptom subgroups (low and high) were identified based on the trajectories of the 
psychological symptom cluster of fatigue, depressive symptom and anxiety over the first 18 
months of adjuvant therapy. Younger age [OR=0.92, P<0.001], less education [OR=0.86, 
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P=0.004], and treatment with chemotherapy [OR=1.66, P=0.071] were associated with greater 
odds of being in the high severity psychological symptom cluster subgroup. Polymorphic 
variations in genes related to the HPA axis (i.e., FKBP5 rs9394309 [OR=3.98, P=0.015], NR3C2 
rs5525 [OR=2.54, P=0.036], CRHR1 rs12944712 [OR=3.99, P=0.021]) were also associated with 
membership in the high severity psychological symptom cluster subgroup. Results of this study 
may help healthcare providers to screen and identify postmenopausal women diagnosed with early 
stage breast cancer who are at increased risk for psychological symptoms during adjuvant therapy 
which includes the AI, anastrozole, facilitating the development of individualized and preemptive 
interventions to better manage their symptoms. 
3.3.2  Introduction 
Women with breast cancer commonly experience multiple psychological symptoms throughout 
their cancer diagnosis and treatment trajectory (Park et al., 2018; Tsaras et al., 2018). According 
to a systematic review, approximately 39%  and 27.2%  women with breast cancer will experience 
long-term depressive symptom and anxiety, respectively, five years after a cancer diagnosis 
(Maass, Roorda, Berendsen, Verhaak, & de Bock, 2015). Psychological symptoms are highly 
correlated with somatic symptoms (Leonhart et al., 2017). Increasing evidence shows that fatigue, 
depressive symptom and anxiety frequently cluster together among women with breast cancer 
(Bower et al., 2011; Doong et al., 2015; Ho et al., 2015).  Results from our previous longitudinal 
study of symptom clusters among women with breast cancer also suggests that these symptoms 
form a psychological symptom cluster, with possible concurrent symptoms of “sleep disturbance”, 
and “cognitive impairment”. These psychological symptoms have a detrimental impact on 
92 
cognitive function, adherence to treatment and can compromise the patients’ quality of life (QOL) 
(Biglia et al., 2012; Ng et al., 2015; Pitman, Suleman, Hyde, & Hodgkiss, 2018). 
The etiologies of fatigue, and depressive symptom and anxiety are multifactorial. Although 
the reason for the clustering of these psychological symptoms remains unclear, it is widely 
suggested that cytokines, which act on the central nervous system, may play a role by inducing 
sickness behaviors (Cleeland et al., 2003). Women with breast cancer experience high levels of 
stress from cancer diagnosis and throughout undergoing cancer treatment with the activation of 
inflammatory response are at high risk for developing psychological symptoms (Miller, Ancoli-
Israel, Bower, Capuron, & Irwin, 2008). Peripheral levels of proinflammatory mediators are 
controlled by a number of physiological pathways. Key among them is the hypothalamic-pituitary-
adrenal (HPA) axis, which has a complex and bidirectional relationship with the immune system 
(Chrousos, 1995). Research shows that the HPA axis can be suppressed by chemotherapy and 
radiation therapy during cancer treatment (Schmiegelow et al., 2003), which may contribute to 
increased inflammation. Other factors, such as psychological stress related to cancer diagnosis and 
treatment, can also induce inflammation and disrupt the HPA axis (Marsland, Walsh, Lockwood, 
& John-Henderson, 2017; Spiegel et al., 2006). Although no study has evaluated the influence of 
endocrine therapy on inflammation and the HPA axis among women with breast cancer, a 
significant body of work suggests that higher levels of estrogen has an anti-inflammatory effect 
(Kovats, 2015), which can stabilize the function of the HPA axis (De Nicola, Saravia, Beauquis, 
Pietranera, & Ferrini, 2006). The estrogen levels of postmenopausal women with breast cancer are 
substantially reduced due to the effect of aromatase inhibitor (AI) therapy and the change of 
menopausal status (Lønning, 1996).  Therefore, activation and disruption of the HPA axis during 
cancer treatment and subsequent modulation of levels of proinflammatory mediators may 
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contribute to individual differences in vulnerability to clusters of psychological symptoms. In 
support of this possibility, research shows that disrupted HPA axis activity has been linked with 
psychological symptoms among cancer patients. Hoyt and colleagues found that sleep disruption 
and depressive symptom were related to disrupted cortisol activity (Hoyt et al., 2016). Similarly, 
another study showed that a symptom cluster of pain, depressive symptom, and fatigue was 
associated with increased level of cortisol and adrenocorticotropic hormone levels among women 
with breast cancer (Thornton et al., 2010). The regulation of peripheral inflammation by the HPA 
axis is influenced by both peripheral levels of cortisol and the sensitivity of glucocorticoid 
receptors (GR) in immune cells to its anti-inflammatory properties (Miller, Ancoli-Israel, Bower, 
Capuron, & Irwin, 2008). A number of genetic polymorphisms have been identified that can 
influence magnitude of HPA axis activity and sensitivity of GR receptors. Moreover, a number of 
these polymorphisms  (e.g., FKBP5, CRHR1, CRHR2, NR3C1) are associated with a higher risk 
of post-traumatic stress disorder and depressive disorder (Carvalho, Coimbra, Ota, Mello, & 
Belangero, 2017; Rao et al., 2016; Watkins et al., 2016). This raises the possibility that variation 
in genes that regulate activity and sensitivity of the HPA axis may contribute to the experience of 
comorbid psychological symptoms among women with breast cancer.  
To date, studies have focused on the experience of clusters of symptoms among women 
with breast cancer who are receiving chemotherapy (Kim et al., 2014). Results suggest that 
symptoms of pain, fatigue, sleep difficulty and depressive symptom cluster within these patients 
over time. The trajectory of the psychological symptom cluster among women receiving long-term 
endocrine therapy is less well characterized and factors that may impact risk for these symptoms 
are poorly understood. Based on evidence that the HPA axis plays a role in the modulation of 
peripheral inflammatory mediators that can result in sickness and psychological symptoms, 
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including fatigue, depressive symptom and anxiety, it is possible that genetic polymorphisms that 
relate to variation in HPA axis function may contribute to risk for the psychological symptom 
cluster among women with breast cancer.  
Accordingly, the purpose of this study is to: (1) identify subgroups of women with breast 
cancer with distinct experiences with the psychological symptom cluster from baseline through 
the first 18 months of systemic adjuvant therapy; and (2) explore associations between 
demographic and clinical characteristics and variation in genetic polymorphisms related to HPA 
axis function and symptom subgroup membership.  
3.3.3  Methods 
3.3.3.1 Study design 
This is an analysis of existing symptom data and newly generated genomic data from a 
prospective repeated measures study of cognitive function in postmenopausal women receiving 
the AI, anastrozole, for early stage breast cancer (R01-CA107408) (Bender et al., 2015). 
Symptom data were collected every 6 months from baseline (after surgery and pre-adjuvant 
therapy) to 18-months post initiation of adjuvant therapy. Genetic data were collected from DNA 
extracted from blood or saliva samples. 
3.3.3.2 Sample and setting 
Two cohorts of postmenopausal women with early stage breast cancer who had completed surgery 
were recruited from the Breast Cancer Program of the Hillman Cancer Institute. One group of 
women was only prescribed anastrozole therapy (AnastOnly) and the other group of women was 
prescribed chemotherapy followed by anastrozole therapy (ChemoAnast). The original study was 
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approved by the University of Pittsburgh Institutional Review Board, and all participants provided 
written informed consent. 
 Women were included if they were newly diagnosed with stage I, II or IIIA breast cancer, 
postmenopausal, less than 75 years old, scheduled to receive chemotherapy plus anastrozole or 
anastrozole alone, abled to speak and read English and had completed a minimum of 8 years of 
education. Women were excluded if they had self-reported psychiatric illness within the previous 
2 years, a prior diagnosis of a neurologic illness or cancer, or clinical evidence of distant 
metastases. For this analysis, we only included women who had symptom data for at least two of 
the time points from baseline to 18 months after adjuvant therapy initiation (N=292). 
3.3.3.3 Measures 
Self-reported demographic information and clinical characteristics from medical records were 
collected at baseline, including age, race, education level, occupation type, marital status, disease 
stage, and types of treatments. 
3.3.3.4 Symptom measures 
Two subscales of the Profile of Mood States (POMS) (Fatigue/Inertia subscale and 
Tension/Anxiety subscale) were used to measure fatigue and anxiety. The POMS is a self-reported 
measure of mood states, with 65-items rated on a 5-point Likert scale format ranging from 0 (not 
at all) to 4 (extremely) (McNair et al., 1992). The POMS-Fatigue/Inertia subscale has 7 items, 
with a test-retest reliability of 0.66 and internal consistency of 0.94 (McNair et al., 1992). 
The POMS-Tension/Anxiety subscale has 9 items, with an internal consistency of 0.92 and test-
retest reliability of 0.70 (McNair et al., 1992). Higher average fatigue and anxiety subscale scores 
(range 0-4) indicate a greater severity of fatigue and anxiety.
96 
The Beck Depression Inventory-II (BDI-II), a 21-item, self-reported measure in which 
depressive symptom severity is rated on a 4-point Likert scale ranging from 0 (no symptoms) to 3 
(severe symptoms) (Beck et al., 1996).  High reliability and validity have been demonstrated for 
the BDI (Wang & Gorenstein, 2013). The BDI-II measures somatic symptoms (items 15-21) and 
mood/cognitive symptoms (items 1-14) (Thombs et al., 2010). For this study, the total score of 
items 1-14 was used to measure depressive symptom to avoid the influence of other treatment 
related symptoms. Higher total scores for the 14 items indicate more severe depressive symptoms. 
3.3.3.5 Genotypic measures 
Among participants who provided a blood sample for genetic analyses(n=184), those providing 
blood had genomic deoxyribonucleic acid (DNA)was extracted from white blood cells using the 
simple salting-out method (Miller et al., 1988). If blood was unavailable, DNA was extracted from 
saliva using prepIT•L2P (Genotek, 2016). Samples were genotyped using the iPLEX MassArray 
platform which has excellent with proven accuracy (>99.7% concordance rate). To control the 
quality of genetic data, Hardy-Weinberg p-values of <0.05 and SNPs with call rates of <95% were 
excluded.  
Based on the knowledge that the HPA axis plays a key role in the control of peripheral 
levels of proinflammatory mediators that communicate with the central nervous system to 
coordinate comorbid psychoneurological symptoms, we focused only on genes and SNPs that are 
directly related to the HPA axis. A review of functional SNPs of genes associated with the HPA 
axis in the general population was conducted. Search terms “single nucleotide polymorphism”, 
“gene” and “HPA axis” were used in the initial search, which identified 33 genes and 118 SNPs. 
We employed a review of the literature to narrow our examination of genes to those that play a 
direct and major role in HPA regulation (Arnett et al., 2016). Although many candidate genes can 
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influence the function of the HPA axis, genes related to glucocorticoid receptors (NR3C1, 
FKBP5), mineralocorticoid receptor (NR3C2), and corticotropin-releasing hormone (CRHR1, 
CRHR2, CRHBP) play an important role in the regulation of HPA axis reactivity (Arnett et al., 
2016). Finally, a list of 39 SNPs in these 6 genes that have been associated with HPA regulation 
in the literature were selected for analysis after quality control (See Appendix A, Table 1).  
3.3.3.6 Statistical analysis 
Group-based multi-trajectory modeling was used to classify women with breast cancer into 
subgroups with “similar” psychological symptom cluster trajectories over the course of adjuvant 
therapy. The SAS macro PROC TRAJ (SAS 9.4) (Jones, 2014) was used to perform this analysis. 
Data screening was performed to make sure the assumption for missing data at random was not 
violated and the subsample used for the genetic analysis were random samples from the original 
dataset. First, based on our prior knowledge of symptom clusters trajectory studies (Avis, Levine, 
Case, Naftalis, & Van Zee, 2015; Donovan, Gonzalez, Small, Andrykowski, & Jacobsen, 2013), 
two to five subgroups were fitted in the models. To identify the optimal number of subgroups 
among trajectory models, we used the following the criteria for model selection: (1) highest 
Bayesian Information Criterion (BIC) and (2) average posterior probabilities (AvePP) of class 
membership. To assess model adequacy, the following criteria were used: (1) AvePP of assignment 
should exceed 0.7 for all subgroups, (2) the odds of correct classification (OCC) should exceed 5 
for all subgroups, and (3) close correspondence between the estimated probability of group 
membership and the proportion classified in that group (Nagin & Odgers, 2010). The parameters 
of the unconditional multi-trajectory modeling included the probability of membership in each 
subgroup’s trajectory and the regression coefficients (b0 =intercept, b1 =linear, or b2 =quadratic) of 
each subgroup’s trajectory. The significance level was set at 0.05.  
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Binary logistic regression analysis was used to explore the associations between 
demographic and clinical predictors and predicted trajectory subgroup membership. Univariate 
analyses were used initially to identify potential significant predictors (p<0.10) to include in the 
multivariable models. Age, marital status, race, education, employment, stage of disease, and 
treatment of chemotherapy were evaluated as potential predictors.  
Binary logistic regression was used to explore the relationship between each genetic model 
for each SNP (additive, dominant, recessive) and the predicted trajectory subgroup membership. 
Significant demographic and clinical predictors were included in the binary logistic models at 
potential covariates. Univariate analyses were initially performed for each SNP. Each possible 
SNPs with p<0.10 identified in the univariate analyses were evaluated one at a time in the 
multivariate model controlling for significant covariates. Only significant SNPs (p<0.05) 
controlling for covariates were reported in the final results. Goodness of fit, covariate-adjusted 
odds ratios (ORs) and 95% confidence intervals were reported to estimate the magnitude 
and precision of the association between predictors variables and predicted subgroup membership. 
3.3.4  Results 
3.3.4.1 Trajectory of two subgroups 
The response profiles/trajectories identified via multi-trajectory modeling for each of the three 
symptoms are included Table 13 and Figure 4. Two distinct trajectory subgroups (low and high) 
were identified from multi-trajectory modeling based on the trajectories of fatigue, depressive 
symptoms and anxiety with best fit based on selection and diagnostic criteria (BIC=-9555.55, 
AvePPlow group=97.5%, AvePPhigh group=95.7%, OCClow group=11, OCChigh group=77). Approximately 
22.6% of women were classified in the high trajectory group. In the high group, self-reports of 
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fatigue and depressive symptoms remained high from baseline to 18 months (b0,fatigue = 42.487, 
b0,depressive symptom = 12.883). However, significant linear and quadratic effects were also found for 
anxiety in the high group (b0 = 51.928, b1 = -14.536, and b2 = 2.795).  As shown in Figure 4, 
anxiety was high at baseline, declined from baseline to 6 months and then slightly increased after 
12 months. In the low group, self-reports on fatigue and depressive symptoms remained low from 
baseline to 18 months (b0,fatigue = 12.219, b0,depressive symptom = -2.175), whereas anxiety declined 
linearly from baseline to 18 months (b0 =15.501, b1 = -1.282) in the low group. The estimated 
parameters reported in Table 13 were the intercept, linear and quadratic terms of the latent variable, 
not the predicted mean on the trajectory plot in Figure 4. Trajectory mean calculation is complex 
and uses the equation developed by Nagin (2005, p.32), which takes into account the impact of 
censoring. 
Table 13 Group-Based Trajectory Model Profiles 
Predicted 
Trajectory 
Group 
Membership 
Symptoms 
Model Parameter (SE), p-value 
Intercept Linear        Quadratic 
Low Severity 
(77.37%) 
Fatigue 12.22 (0.97), p<.001 N/A N/A 
Depression symptom -2.18 (0.59), p<.001 N/A N/A 
Anxiety symptoms 15.50 (1.14), p<.001 -1.28 (0.42), p=.002 N/A 
High Severity 
(22.63%) 
Fatigue 42.49 (1.93), p<.001 N/A N/A 
Depression symptom 12.88 (1.02), p<.001 N/A N/A 
Anxiety symptoms 51.93 (5.10), p<.001 -14.54 (4.50), p=.001 2.76 (0.93), p=.003 
Note: SE=standard error 
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Figure 4 Trajectories of Fatigue, Depressive Symptoms and Anxiety 
Table 14 Demographic and Clinical Characteristics Between Predicted Trajectory Subgroup 
Characteristic Low Group 
(n=225) 
High Group 
(n=67) 
Univariate Multivariate 
Mean ± SD OR (95%CI) 
Age (years) 61.92 ± 6.18 58.69 ± 5.28 0.92 (0.87, 0.96)*** 0.91 (0.86, 0.95)*** 
Education (years) 15.15 ± 2.93 14.03 ± 2.24 0.86 (0.77, 0.95)** 0.82 (0.73, 0.92)** 
Characteristic   n (%) OR (95%CI) 
Race 
  White 
   Black† 
218 (96.9%) 
7 (3.1%) 
64 (95.5%) 
3 (4.5%) 
1.46 (0.37, 5.81) - 
Systemic therapy 
   Chemotherapy plus AI         
   AI only† 
80 (35.6%) 
145 (64.4%) 
32 (48.8%) 
35 (52.2%) 
1.66 (0.96, 2.88)*       - 
Stage of disease 
     I† 
IIA 
IIB 
IIIA 
144 (64.0%) 
49 (21.8%) 
19 (8.4%) 
13 (5.8%) 
42 (63.6%) 
14 (21.2%) 
5 (7.6%) 
5 (7.6%) 
0.98 (0.49, 1.95) 
0.90 (0.32, 2.56) 
1.32 (0.45, 3.91) 
- 
Currently married/partnered 
Yes 
    No† 
158 (79.2%) 
67 (29.8%) 
43 (64.2%) 
24 (35.8%) 
0.76 (0.43, 1.35) 
- 
Currently Employed 
Yes(part-time & full time) 
    No† 
157 (69.8%) 
68 (30.2%) 
49 (73.1%) 
18 (26.9%) 
1.18 (0.64, 2.17) 
- 
Note: *p<0.1, **p<0.01, ***p<0.001, † reference group. 
Note: OR=odds ratio; AI=aromatase inhibitor. 
Note: Univariate analyses were used initially to identify potential significant predictors (p<0.1). Only significant 
predictors were included in the multivariable models. 
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3.3.4.2 Associations between demographic and clinical characteristics and predicted 
trajectory subgroup membership 
Demographic and clinical characteristics of the two predicted trajectory subgroups are shown in 
Table 14. The initial univariate analysis included age, race, education, marital status, employment 
status, stage of disease and treatment of chemotherapy. Based on univariate logistic regression age 
(p<0.001), education (p=0.004) and treatment of chemotherapy (p=0.073) were associated with 
predicted symptom subgroup membership. Results from the multivariate binary logistic model 
including only the candidate predictors meeting the screening threshold of p<0.10 showed that 
women in the high group were significantly younger (OR=0.82, p<0.001), had less education 
(OR=0.91, p=0.001) than women in the low group.  
3.3.4.3 Associations between SNPs and predicted trajectory subgroup membership 
Three SNPs associated with glucocorticoid receptor FKBP5, mineralocorticoid receptor NR3C2, 
and corticotropin-releasing hormone CRHR1 were significant in the binary logistic regression after 
controlling for age, education, and treatment of chemotherapy (see Table 15). Other covariate-
adjusted findings for all of the SNPs used in the analysis are listed in Appendix A Supplement 
Table 1. In the regression analysis for FKBP5 rs9394309, for women carrying two common A 
alleles (i.e., AA), the odds of being in the high group membership were 4 times greater than women 
carrying one or two minor G alleles (i.e., AG+GG). In the regression analysis for NR3C2 rs5525, 
for women carrying one or two minor A alleles (i.e., GA+AA), the odds of being in the high group 
membership was 3 times higher than the odds of women carrying two common G alleles (i.e., GG). 
In the regression analysis for CRHR1 rs12944712, for women carrying one or two minor A alleles 
(i.e., GA+AA), the odds of being in the high group membership was 4 times larger than for those 
with two common G alleles (i.e., GG).  
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Table 15 Multivariate Binary Logistic Regression Models for Genotypic Predictors of Predicted Subgroup 
Membership 
Predictor OR SE 95% CI Z  P Value 
FKBP5 rs9394309 3.98 0.57 [1.31,12.08] 5.953 .015* 
Age 0.88 0.05 [0.81, 0.96] 7.794 .005* 
Education 0.84 0.09 [0.70, 1.01] 3.363 .067 
Chemotherapy 2.59 0.49 [1.00, 6.72] 3.837 .051 
Overall model fit: χ2= 7.704, df=8, p=.463, pseudo R2 =.147 
NR3C2 rs5525 2.54 .44 [1.06, 3.60] 4.396 .036* 
Age 0.89 .04 [0.83, 0.96] 8.594 .003** 
Education 0.87 .08 [0.74, 1.01] 3.230 .072 
Chemotherapy 1.54 .43 [0.66, 3.60] 1.010 .315 
Overall model fit: χ2=12.393, df=8, p=.135, pseudo R2 =.112 
CRHR1 rs12944712 3.88 .59 [1.23, 12.28] 5.331 .021* 
Age 0.90 .04 [0.84, 0.97] 6.885 .009** 
Education 0.86 .08 [0.84, 0.97] 3.134 .077 
Chemotherapy 1.71 .23 [0.72, 4.10] 1.458 .227 
Overall model fit:    χ2=6.614, df=8, p=.579, pseudo R2 =.123 
Note: * means p<.05, ** means p<.01; SE=standard error; OR=odds ratio; CI=confidence interval. 
Note: Low group is the reference group; Genotypic predictors evaluated in the models were FKBP5 rs9394309 (AA 
versus AG+GG), NR3C2 rs5525 (GA+AA versus GG), and CRHR1 rs12944712 (GA+AA versus GG).  
Note: Age, and education are reported in years. Chemotherapy is reported as Yes or No, No is the reference group. 
3.3.5  Discussion 
This is the first study to explore associations between variability in genes related to the HPA axis 
and risk for the clustering of fatigue, depressive symptom and anxiety among women with early-
stage breast cancer. By using group-based multi-trajectory modeling, we were able to identify 
subgroups of patients based on multiple psychological symptoms trajectories at the same time. 
Traditional group-based trajectory modeling can only estimate the trajectory for a single symptom. 
3.3.5.1 Psychological symptom cluster trajectories and phenotypic profiles 
In this study, two groups of women (low versus high trajectory) were identified based on reported 
psychological symptoms trajectories. Depressive symptom and fatigue were generally stable and 
persistent for both groups. Similar to our finding, Avis et al. (2013) also found that depressive 
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symptom was stable and low among older women with breast cancer (> 65 years old) when 
measured 18 months after cancer diagnosis. However, depressive symptom was initially high and 
significantly decreased after cancer diagnosis among younger women with breast cancer (<65 
years old). Bidstrup et al. (2015) identified three subgroups based on depressive symptom 
trajectories and showed that depressive symptom decreased from baseline (before surgery) to eight 
months post-surgery. Our results regarding the group trajectory of anxiety from baseline to 12 
months were consistent with other trajectory studies, all subgroups had highest anxiety severity at 
baseline and then slightly decreased or plateaued during cancer treatment (Bidstrup et al., 
2015;Saboonchi, Petersson, Wennman-Larsen, Alexanderson, & Vaez, 2015). It is interesting to 
note that we observed a slight increase in anxiety from 12 months to 18 months in the high group. 
Additional research is needed to confirm these results and explore the reasons why anxiety 
increased during this period in the high group. In another fatigue trajectory study, Bower et al. 
(2018) tracked fatigue for five years after primary treatment (after surgery, chemotherapy and 
radiation therapy) and identified five trajectory subgroups. The very low and high groups had 
stable and persistent fatigue; however, linear and quadratic changes were observed in the other 
groups. Differences in the results of these studies may be due to different sample characteristics, 
and assessment times. Compared to these studies, our study had an older population 
(postmenopausal women) and different baseline assessment point (after surgery but before 
adjuvant therapy). Overall, all these studies provide evidence that depressive symptom, anxiety 
and fatigue did not disappear but persisted during and long after cancer treatment. Therefore, health 
care providers should address the psychosocial needs of women from cancer diagnosis and 
throughout their treatment trajectory. 
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In terms of phenotypic predictors, the results from our binary logistic regression showed 
that younger age, less education and treatment of chemotherapy were associated with a higher 
symptom severity. Consistent with our findings, Doong et al. (2015),  reported that higher severity 
of a cluster of pain, fatigue, sleep disturbance and depressive symptom was inversely associated 
with age, non-white race, and less education among women with breast cancer. In the Bidstrup et 
al. (2015) study, younger age and receiving chemotherapy were associated with higher 
psychological distress, anxiety and depressive symptom among women with breast cancer. It is 
possible that women with higher education levels may have more information and a better 
understanding of the disease process and treatment side effects. Therefore, an integrated team of 
health care providers with expertise in psycho-educational interventions may help oncologists to 
reduce the burden of depressive symptom and anxiety, especially among younger women with less 
education (Ram, Narayanasamy, & Barua, 2013). In addition to age, education and treatment 
characteristics of patients, race, income, disease characteristics (Doong et al., 2015), comorbidity 
score (Doong et al., 2015), body mass index (Bower et al., 2018), childhood trauma (Han et al., 
2016), loneliness (Jaremka et al., 2013), and physical inactivity (Winters-Stone, Bennett, Nail, & 
Schwartz, 2008) have been shown an associated with fatigue, depressive symptoms and anxiety 
among women with breast cancer in other studies. It is possible that different phenotypic predictors 
can interact with each other and influence the symptom experience. For example, established 
research shows that the accelerated aging that accompanies cancer and cancer therapy may 
influence cognitive function among cancer patients (Mandelblatt et al., 2013). Future studies are 
needed to examine the complex relationships between phenotypic predictors and psychological 
symptoms experienced among women with breast cancer. 
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3.3.5.2 HPA axis related genes and subgroup membership 
It is known that certain genetic polymorphisms can influence the regulation of HPA axis and GR 
sensitivity (Binder, 2009). Variation of the psychological symptom experience has been 
hypothesized to stem from some genetic variations in the HPA axis through the regulation of 
HPA axis function and characterized by hyperactive of the HPA axis, decreased GR sensitivity 
and enhanced inflammation. In this study, we identified three SNPs of genes associated with 
HPA axis that were related to the psychological symptom experience. 
Women who were heterozygous for the minor A allele of CRHR1 rs12944712 had higher 
incidence of more severe psychological symptoms. The frequency of A allele in our sample 
(A=0.44) was higher than the general population (A=0.35). Consistent with our finding, minor A 
allele of CRHR1 rs12944712 has been linked with major depressive disorder (da Silva et al., 2016), 
posttraumatic stress symptoms (White et al., 2013), and moderation of the stress-related physical 
health (Lessard & Holman, 2014) in non-cancer populations. CRHR1 is a G-protein coupled type 
I CRH receptor, which plays an important role in activation of the HPA axis following stress 
(Mahon, Zandi, Potash, Nestadt, & Wand, 2013). Other polymorphisms of CRHR1 gene have been 
associated with increased cortisol reactivity (Sheikh, Kryski, Smith, Hayden, & Singh, 2013), and 
increased pharmacologically-induced cortisol response among children with maltreatment (Tyrka 
et al., 2009). These evidences suggest that CRHR1variants can interact with environment to impact 
cortisol reactivity and stress sensitivity and increase the risk of psychological related symptoms 
and disorders. Future research is needed to evaluate psychological symptoms with polymorphisms 
of CRHR1 gene and the interaction with environment (i.e., childhood maltreatment, stressful life 
events) together among cancer patients. 
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Women who were homozygous for the common A allele of FKBP5 rs9394309 had a higher 
severity of psychological symptoms. The frequency of A allele in our sample (A=0.77) can 
represent the frequency of A allele in the general population (A=0.75). Consistent with our finding, 
other studies also found that the common A allele of rs9394309 is associated with major depression 
(Szczepankiewicz et al., 2014), and increased cortisol secretion in non-cancer populations (Velders 
et al., 2011). Increasing evidence suggests that variation of polymorphisms of FKBP5 (i.e., 
rs9296158, rs3800373, rs1360780, rs947008, rs755558, rs3800373) are associated with a higher 
risk of post-traumatic stress disorder (Watkins et al., 2016), musculoskeletal pain (Bortsov et al., 
2013), and major depressive disorders (Rao et al., 2016) in non-cancer populations. rs9394309 is 
located on intro 10 of the FKBP5 gene. The primary role of FKBP5 is to inhibit GR signaling and 
decrease GR sensitivity by interacting with heat-shock protein 90 (Hsp90) as a co-chaperone 
(Binder, 2009). Common SNP (rs1360780) in FKBP5 is associated with increased expression of 
FKBP5, decreased GR sensitivity and less negative feedback of the HPA axis (Zannas, 
Wiechmann, Gassen, & Binder, 2016), evidenced by increased cortisol response and depressive 
symptoms (Höhne et al., 2015; Velders et al., 2011). Moreover, increased FKBP5 production 
promotes NF-κB related inflammation with a positive association with pro-inflammatory 
cytokines (Zannas et al., 2019). This evidence suggest that variants of FKBP5 seem to modulate 
GR sensitivity through the role in regulation of HPA axis, resulting in enhanced inflammation and 
increasing the risk of psychological symptoms. Given the function of FKBP5 in GR signaling and 
stress response, further research is needed to expand the sample size and examine the variation of 
polymorphisms, gene expression, epigenetic changes of the FKBP5 gene and the related 
psychological symptoms among cancer patients.  
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Women who were heterozygous for the minor A allele of NR3C2 rs5525 had more severe 
psychological symptoms. The frequency of A allele in our sample (A=0.11) is similar to the 
frequency of A allele in the general population (A=0.12). NR3C2 is a mineralocorticoid receptor 
(MR), which is a high-affinity receptor for glucocorticoids, and plays an important role in tonic 
inhibitory control of the HPA axis activity (ter Heegde, De Rijk, & Vinkers, 2015). Decreased MR 
expression and functionality in the hippocampus are found in patients with depression (Medina et 
al., 2013). It has been shown that genetic variation in NR3C2 (i.e., rs5522, rs2070951) can change 
MR expression and the function of MR protein and are associated with enhanced responses in 
cortisol secretion (DeRijk et al., 2006). MR activity can influence inflammatory response through 
regulation of NF-κB and pro-inflammatory cytokine production (Chantong, Kratschmar, Nashev, 
Balazs, & Odermatt, 2012). This evidence suggests that MR variants may play a role in the 
development of psychological symptoms characterized by increased inflammation and 
hyperactivity of the HPA axis with increased cortisol secretion. Little research has identified 
genetic variation at this locus (rs5525) with psychological symptoms. One study shows that genetic 
variation in rs5525 is associated with verbal memory performance (Keller et al., 2017). More 
studies are needed to confirm the association between rs5525 and other psychological related 
symptoms (i.e., cognitive function, pain, fatigue) among cancer patients.  
This evidence suggests that genes involved in regulating the HPA axis and GR sensitivity 
also associated with susceptibility to psychological symptom trajectories among women with 
breast cancer. Genetic variation in HPA axis sheds light on the mechanisms underlying the 
psychological symptoms. Future studies can assess biological biomarkers and epigenetic changes 
related to the HPA axis to help us better understand the underlying mechanisms of psychological 
symptoms thus allowing interventions to be developed related to biomarkers to reduce the burden 
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of symptoms among cancer patients. The results of this study emphasize the need for personalized 
medical care for symptom management. These genetic feature, demographic and clinical 
characteristics can be used to personalize the prediction of psychological symptoms among women 
with breast cancer.  
Some limitations of this study are important to acknowledge. First, the majority of our 
sample was Caucasian women. Therefore, generalizability of the study results is limited due to the 
racial homogeneity of the sample. Symptom profiles and allele frequencies may be different 
among different ethnic groups. Secondly, we did not assess the patient’s personality, or general 
physical and mental health status. In addition to cancer diagnosis and cancer treatment, personality, 
comorbidity, and general health status may contribute to the course of psychological symptoms.  
Future research is needed to take these factors into consideration and have a healthy age-matched 
control group for comparison. In addition, because this was an exploratory analysis, our study did 
not correct for multiple testing of the associations between polymorphisms in HPA axis related 
genes and the subgroup membership of the psychological symptom cluster. This exploratory study 
lays the initial groundwork for future studies. Replication in a larger sample is needed to confirm 
the relationships between phenotypic predictors and the symptom trajectory subgroup 
membership. 
3.3.6  Conclusion 
Two distinct symptom subgroups (low and high) were identified based on the predicted trajectories 
of symptoms of fatigue, depressive symptom and anxiety. Fatigue and depressive symptom were 
stable high or low over the course of adjuvant therapy. Women experienced highest anxiety before 
starting any adjuvant therapy. Women of younger age, less education with lesser degree and those 
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that received chemotherapy had a higher burden of psychological symptoms. Our findings provide 
new evidence that genetic variation associated with activation and sensitivity to the HPA axis 
(FKBP5 rs9394309, NR3C2 rs5525, and CRHR1 rs12944712) are associated with the severity of 
the psychological symptom cluster of fatigue, depressive symptom and anxiety among women 
with breast cancer. The association between genes, polymorphisms and symptoms provides further 
support for the role of the HPA axis mechanism in the clustering of psychological symptoms. The 
results of this study will directly help healthcare providers to identify and screen women with 
breast cancer and identify those who are at higher risk of more severe psychological symptoms 
across the first 18 months of adjuvant therapy.  
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Appendix A SUPPLIMENT MATERIALS 
A.1 SUPPLIMENT TABLES
Table 1 Final list of single nucleotide polymorphisms for genetic analysis 
Gene SNP Alleles MAF HWP p-value Model 
CRHR2 
rs255098 A>G 0.38 0.63 0.470 R 
rs3779250 T>C 0.36 0.67 0.206 D 
NR3C1 
rs41423247 G>C 0.33 0.24 0.557 D 
rs258747 A>G 0.4 n/a n/a n/a 
rs10482605 A>G 0.18 0.3 0.193 D 
rs6191 C>A 0.49 0.08 0.257 D 
rs258813 G>A 0.29 0.11 0.478 D 
rs33388 A>T 0.49 0.06 0.469 R 
rs10052957 G>A 0.31 0.54 0.568 R 
rs6198 T>C 0.17 0.12 0.298 R 
rs 6189 C>A 0.03 0.64 0.295 R 
rs6190 C>T 0.02 0.71 0.288 D 
FKBP5 
rs1360780 C>T 0.29 n/a n/a n/a 
rs3800373 A>C 0.26 n/a n/a n/a 
rs4713916 G>A 0.28 n/a n/a n/a 
rs9296158 G>A 0.29 0.24 0.145 R 
rs9394309 G>A 0.23 0.28 0.015 D 
rs3777747 A>G 0.47 0.45 0.284 R 
rs17542466 A>G 0.15 n/a n/a n/a 
rs2766533 G>A 0.42 0.96 0.177 R 
rs9380526 T>C 0.30 n/a n/a D 
rs9394314 A>G 0.28 0.76 0.091 D 
rs2817032 T>C 0.28 0.21 0.126 R 
rs2817040 G>A 0.27 n/a n/a n/a 
rs7753746 A>G 0.14 0.83 0.209 D 
rs4713902 T>C 0.32 n/a n/a n/a 
rs7748266 C>T 0.17 0.97 0.087 D 
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rs7757037 G>A 0.34 n/a n/a n/a 
NR3C2 
rs5525 G>A 0.12 0.55 0.036 R 
rs4835488 T>C 0.46 0.43 0.096 R 
rs10213471 G>A 0.14 0.55 0.253 R 
rs2070951 G>C 0.43 0.19 0.755 R 
CRHBP 
rs10473984 G>T 0.06 0.84 0.977 R 
rs7718461 A>G 0.43 0.22 0.377 D 
rs1875999 T>C 0.35 0.96 0.777 R 
CRHR1 
rs17689918 G>A 0.20 0.64 0.405 R 
rs4458044 G>C 0.29 0.55 0.126 D 
rs242924 C>A 0.45 0.65 0.068 D 
rs1768996 T>A 0.33 0.1 0.207 R 
rs12944712 G>A 0.46 0.91 0.021 R 
rs12938031 A>G 0.40 0.83 0.308 D 
rs4792887 C>T 0.09 0.98 0.294 R 
rs1396862 C>T 0.21 0.82 0.470 R 
rs17763104 G>A 0.15 0.21 0.740 R 
rs110402 C>T 0.46 0.55 0.102 R 
rs242948 A>C 0.39 0.7 0.065 D 
rs1876828 G>A 0.20 0.66 0.443 D 
rs17689882 G>A 0.20 0.81 0.266 R 
rs12936511 C>T 0.04 0.29 0.889 D 
rs242941 G>T 0.32 0.41 0.160 D 
Note: A=additive model; R=recessive model; D=dominant model; HWE=Hardy-Weinberg Equilibrium; MAF=minor 
allele frequency; SNP=Single Nucleotide Polymorphism. n/a=failed assay or SNP violated Hardy-Weinberg 
expectations (p < 0.05). All models are adjusted for age, education level and treatment of chemotherapy. In all models, 
p-values from binary logistic regression are reported.
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